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Abstract 
 
Acceptance and Commitment Therapy is a third wave behavioural therapy, 
which encourages individuals to stop fighting their internal experiences (e.g. 
thoughts, feelings, and memories) and teaches individuals techniques to help them 
accept these internal experiences for what they are.  SmartQuit™ is a smartphone 
application for smoking cessation based on Acceptance and Commitment Therapy 
principles. SmartQuit™ consists of eight effective activities, each of which 
provides the user with techniques to deal with cravings to smoke cigarettes. My 
first aim was to examine whether using SmartQuit™, would lead to reductions in 
cigarette intake. My second aim was to determine whether scores obtained on the 
Commitment to Quit Scale would predict smoking outcomes at post-intervention 
and follow-up phases. I used a single-subject, A-B-A-C design across 10 
participants to examine the feasibility of a smartphone app targeting smoking 
cessation (SmartQuit™), with a New Zealand population. Most participants 
showed a significant reduction in cigarette intake and a noticeable reduction in 
cravings to smoke cigarettes. In conclusion, the results of the current study 
suggest that SmartQuit™ is well suited for smoking cessation, with a New 
Zealand population. However, given the small sample size, a larger evaluation 
may be required.  
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Literature Review 
Smoking (as a Social Problem) 
According to the World Health Organization (2011), tobacco use accounts 
for the largest (inevitable) cause of death worldwide, with global mortality 
statistics reporting 100 million tobacco-related deaths, in the 20th century 
(Ministry of Health, 2009). On an annual basis, a projected 1 billion people 
smoke, and worldwide the cost of tobacco on society is large, with almost 6 
million deaths a year (Roberts, Kerr, & Smith, 2013; World Health Organisation, 
2011). Despite the adverse effects of tobacco behavior being common knowledge, 
it is estimated that smoking trends will continue to rise and the death toll will 
increase to an estimated 8 million deaths per annum by 2030 (World Health 
Organization, 2011). Tobacco-related deaths in New Zealand reveal similar 
patterns, with cigarette smoking accounting for 4500-5000 deaths each year, 
including deaths from second-hand smoke (Phillips, 2013). The high prevalence 
of daily tobacco use is illustrated with New Zealand emerging in the sixth position 
out of 43 countries, countries such as Australia, United States, and Canada 
reported similar smoking rates (Scollo & Winstanley, 2015). 
The smoking epidemic has largely declined over time, with vast reductions 
recorded during the period of 1980-2012 (Ng, et al., 2014). Tobias, Cavana, and 
Bloomfield (2010) noted that, around the 1970s in New Zealand, tobacco use 
peaked, and since then smoking prevalence has dropped from approximately 35% 
to 21% for New Zealand adults. However, in spite of the hefty and steady decline 
of 1% each year in developed countries, the absolute smoking consumption 
remains high, due to population growth (Ng, et al., 2014; Shah & Cole, 2010). 
While reductions have been observed over time in high-income (developed) 
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countries (Abdullah & Husten, 2004), smoking rates continue to rise in low-
middle income (underdeveloped or developing) countries (Goldberg, 2009). 
Furthermore, with changes regarding global trends, it is important to consider 
future projections on the smoking epidemic, signifying the large tobacco-related 
burden amongst developing countries (Maziak, et al., 2004).   
Health costs. 
Prolonged exposure to tobacco has the potential to cause harm to all of the 
systems of the human body and may trigger a wide range of fatal diseases 
(Caponnetto, et al., 2011). Over time, society has become more aware of the 
effects of the smoking epidemic. Although, in spite of the knowledge available on 
the devastating consequences of tobacco use, New Zealanders continue to smoke 
on a regular basis (Maziak, et al., 2004), with 21% of New Zealanders 15-64-
year-olds reporting smoking in 2009 (Ministry of Health, 2010). 
Second-hand smoke. 
Exposure to tobacco is not only dangerous for smokers, but it also has 
detrimental health consequences for bystanders, with there being no safe level of 
exposure to second-hand smoke (Kring, Johnson, Davison, & Neale, 2012). In the 
year 2000, 347 deaths in New Zealand were attributed to second-hand smoke 
(Woodward & Laugesen, 2001). Compared to first-hand smoke, second-hand 
smoke contains much higher concentrations of nicotine, ammonia, tar, and carbon 
monoxide (Kring, Johnson, Davison, & Neale, 2012) exposing non-smokers to 
increased risk of medical conditions such as cardiovascular diseases, lung 
abnormalities, lung cancer, and allergies. The effects of parental smoking amongst 
children can also result in a number of high risks, for instance, the increased 
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likelihood of asthma and bronchitis, and greater risks for birth deficits during 
pregnancy (Kring, Johnson, Davison, & Neale, 2012).    
Population differences. 
Research reveals that the tobacco epidemic does not affect each ethnic 
group equally, demonstrated by a higher prevalence of smoking rates among 
indigenous populations such as Māori and Aboriginal Australians (Glover, et al., 
2013). Māori are a high-risk population for smoking, with 45.8% of Māori adults 
engaging in smoking behaviour, and a two-fold increase for Māori compared to 
non- Māori. Glover et al. (2013) also reported that consequences attributed to 
smoking cigarettes, such as cancer and cardiovascular disease, are also higher for 
Māori when compared to non- Māori.  
The Three Phases of Nicotine Dependence (Initiation, Dependence, and 
Relapse) 
Substances, such as tobacco, are used in the hope of altering states of 
awareness and reducing pain. Practically all people use at least one substance, if 
not more, whether it be coffee, alcohol, aspirin, or cigarettes. The extensive 
availability of such substances encourages potential drug abuse. The initial short-
term effects of such substances are typically pleasing, for instance; aspirin helps 
reduce pain, cigarettes and alcohol act as relaxers, and coffee has stimulating 
properties allowing stay awake (Kring, Johnson, Davison, & Neale, 2012).  
Nicotine and tobacco dependence can be understood with a variety of 
theories and models. The three primary factors that influence tobacco and nicotine 
use are physical, behavioural, and psychological. Physically, users are addicted to 
this substance. Behaviourally, smoking is an addictive habit. Psychologically, 
cigarettes are thought to aid in solving problems, managing stress levels, and act 
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as a tool to both socialise with others and enjoy life (Peterson, Vander Weg, & 
Jaen, 2011).  
Of all tobacco products, cigarettes are the most widely used  (American 
Psychiatric Association, 2013). In the U.S tobacco use begins from a young age 
(before 18 years), with evidence showing that by the age of 18 approximately 
20% of individuals smoke monthly and most go on to become daily smokers; with 
starting smoking after the age of 21 years being very uncommon  (American 
Psychiatric Association, 2013).  
The number of cigarettes smoked do not directly correlate with addiction, 
as, sometimes, having one cigarette is enough for someone to become addicted to 
smoking cigarettes (Peterson, Vander Weg, & Jaen, 2011). Smoking cigarettes is 
a learned behaviour and is most likely to be encouraged by peer pressure and/or 
social imitation. For the majority of individuals, it does not take long for this 
social experiment to turn into a physical addiction (Roberts, Kerr, & Smith, 2013).  
The initiation of tobacco use may be precipitated by a variety of factors 
such as peer pressure, social imitation, and by the personality characteristics of an 
individual (e.g. sensation seeking and impulsivity). For the vast majority of 
smokers, this initial experimentation results in nicotine dependence (Little, 2000; 
Killen et al., 1997). The reinforcing and pleasurable effects of tobacco also play a 
role in the initiation and maintenance of the substance with tobacco producing a 
slight euphoria, relaxation, and a slightly pleasurable rush for individuals 
(D'Souza & Markou, 2011). The acute pharmacological effects of tobacco, such as 
stimulation of euphoria and discharge from stress and anxiety (Little, 2000) serve 
as underlying factors for the uptake or experimentation of smoking. 
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Definition in the DSM5 manual. 
In the Diagnostic and Statistical Manual of Mental Disorders, 5th edition 
(DSM5), tobacco use disorder is defined as a pattern of distress or impairment that 
has been caused by tobacco use and has lasted for a duration of 12 months. To 
meet this diagnosis, individuals must meet at least two of the 11 diagnostic 
criteria: 1) tobacco must have been consumed in larger amounts than was 
intended; 2) there is no control over tobacco use; 3) large amounts of time is spent 
to either acquire tobacco or use it; 4) cravings and/ or urges are experienced to use 
tobacco; 5) tobacco use interferes with other obligations; 6) tobacco is used in 
spite of interpersonal or social problems being triggered by its use; 7) tobacco use 
is given more importance than  recreational, social or occupational activities; 8) 
repeated use of tobacco in dangerous situations; 9) continuous tobacco use in spite 
of having had persistent psychological or physical problems caused by tobacco; 
10) tobacco tolerance; and 11) experiencing symptoms of  withdrawal (American 
Psychiatric Association, 2013). 
According to the American Psychiatric Association (2013), tobacco use 
disorder is supported through a number of features, which include smoking on a 
daily basis, getting up during the night to smoke, smoking within 30 minutes after 
having woken up, and consuming a high number of cigarettes during the day 
(American Psychiatric Association, 2013). 
Triggers for maintenance and nicotine dependence. 
Both regular smoking and nicotine dependence usually follow a long-
lasting course, ranging from years to decades  (Peterson, Vander Weg, & Jaen, 
2011). Factors that maintain nicotine dependence include the reinforcing effects of 
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nicotine, sensitisation and tolerance to nicotine, conditioning processes, stress, 
withdrawal symptoms, relapse, and conditioning processes (Little, 2000). 
At the social level, both interest and access to substances are strongly 
influenced by the media, peer behaviour, cultural norms, parents, socialisation, 
acceptable behaviour (Kring, Johnson, Davison, & Neale, 2012), and by social 
comparisons (Lapointe, 2008). The social setting then presents frequent cues to 
the individual to use and purchase tobacco resulting in an increased likelihood for 
engaging in smoking behaviour  (Jha, et al., 2006).   
Studies conducted on human and animal substance abuse, and analyses 
from twin studies show that genetic factors play a role in the susceptibility and the 
persistence to smoke (Bergen & Caporaso, 1999), nicotine dependence has been 
recognised as a psychopharmacologic mechanism that upholds cigarette behaviour 
(Bergen & Caporaso, 1999). Under the pharmacologic theory, addiction is 
sustained through nicotine, as nicotine acts on receptors in the brain, which 
release neurotransmitters and dopamine (Little, 2000). Individuals then continue 
to smoke, as they wish to avoid the neurobiological and physical withdrawal 
symptoms associated with abrupt cessation (Bergen & Caporaso, 1999; D'Souza 
& Markou, 2011).  
Smoking behaviour is associated with a number of psychological factors 
that include beliefs, feelings and thoughts about the world, as well as beliefs about 
oneself, the future and tools for stress management. Stress is considered the most 
significant factor, as many people believe that smoking assists in reducing and 
managing stress. However, research suggests that smoking may actually increase 
stress levels (Peterson, Vander Weg, & Jaen, 2011).  
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Smoking is something that people do, and as a behaviour is subject to 
principles of behavioural learning and conditioning. For instance, individuals who 
smoke come to associate smoking with surrounding stimuli; in the future these 
become triggers (antecedents) for smoking, and consequences, as this social 
reinforcement maintains the smoking behaviour (Peterson, Vander Weg, & Jaen, 
2011). When an individual quits smoking the social reinforcement may be 
replaced by rejection and negativity (punishment) from peers (Tyas & Pederson, 
1998). 
For smokers, the social setting in which they operate also has the potential 
to affect their maintenance of cigarette use. Studies reveal that smokers were more 
likely to smoke with smokers than non-smokers and that smoking took place 
outside the house, bars, and restaurants, as opposed to inside other people’s 
houses, and at the workplace, because they could not smoke in those places due to 
bans (Kring, Johnson, Davison, & Neale, 2012).  
Breaking the habit. 
Approximately 70-80% of smokers want to quit smoking and regret 
initiating smoking (American Psychiatric Association, 2013; Peterson, Vander, 
Weg, & Jaen, 2011; Roberts, Kerr & Smith, 2013; Rondina, Gorayeb, Botelho, 
2007). Of those who attempt to quit, 60% relapse within a week and fewer than 
5% continue to abstinence (American Psychiatric Association, 2013). These 
statistics reveal that very few smokers are able to give up successfully. Most 
individuals will not quit until they are at least 30 years old  (American Psychiatric 
Association, 2013).  
It appears that those that do successfully quit smoking require between 5-7 
quit attempts before they reach successful smoke-free outcomes (Goldberg, 2009; 
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Roberts, Kerr, & Smith, 2013). Motivational, psychological, environmental, 
hereditary, and physiological factors may all have an impact on smoking 
cessation; the most important factor is motivation, as only 12% of smokers are 
prepared to quit (Roberts, Kerr, & Smith, 2013). 
The consequences of quitting. 
Following permanent abstinence, the risk for medical diseases is quick to 
diminish (Caponnetto, et al., 2011). Stopping smoking has many positive effects 
on the overall health of ex-smokers, as it has the potential to extend life 
expectancy, and yield improvements in health (Brannon & Feist, 2009). The age 
at which a person quits can affect the number of years added to an ex-smoker's 
life. Individuals who quit earlier are more likely to have a longer life compared to 
those who quit later (Brannon & Feist, 2009).  Jha et al. (2006) reported similar 
findings and found that those who stopped smoking before the age of 35-69 years 
were 90% more likely to avoid lung cancer. The risk of lung cancer is lower for 
ex-smokers who quit at an earlier age (Brannon & Feist, 2009).  Evidence 
suggests that after having quit for 16 years, all-cause mortality rates return to 
normal and are similar to those of non-smokers. However, ex-smokers are still 
likely to be at a high risk for cancer mortality (Brannon & Feist, 2009).  
Relapse. 
Ex-smokers are vulnerable to relapse for a lengthy period, ranging from 
days, months, to even years following smoking cessation (D'Souza & Markou, 
2011). Borland, Yong, Hyland, and Siahpush (2008) suggested that 22% of 
individuals return to smoking, and smoke cigarettes at a much higher rate than 
before their endeavour to quit. 
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 Consumption of cigarettes can be triggered by exposure to cues and 
contexts that were previously associated with tobacco use (D'Souza & Markou, 
2011). In some instances, just one cigarette is enough to trigger a relapse, and, in 
other instances, relapse takes place following extensive periods of self-restraint 
(Glipan, Pierce, Farkas, & Farkas, 1997). Relapse is also more prevalent for self-
quitters. Evidence shows that two-thirds of self-quitter’s relapse after two days, 
and 75% recommence smoking within six months from their quit attempt 
(Brannon & Feist, 2009). Nicotine dependence can thus be characterised by both 
frequent and related episodes of relapse.  
Evidence-Based Approaches to Quitting Smoking 
There are various types of treatments available for smoking cessation, with 
the main types being: behaviourally, psychologically, and/or pharmacologically 
based. These interventions can be delivered at many levels, such as at the policy 
or governmental level, or at the individual level. Smoking cessation interventions 
may also differ in nature, they can be mainstream, secondary, complimentary, or 
alternative. The availability of alternative modes of interventions gives rise to 
individual preferences when selecting interventions, as this facilitates reach, 
uptake, and choice (Roberts, Kerr, & Smith, 2013).  In this section, I will look 
into the most commonly used evidence-based interventions for smoking cessation. 
Tobacco Control Programme New Zealand. 
New Zealand has one of the most inclusive tobacco control programmes in 
the world. This tobacco-control programme is in line with the directives of the 
tobacco control programme designed by the World Health Organisation. The New 
Zealand-based programme runs regular media campaigns, makes available 
smoking cessation programmes, provides health education, works with other 
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parties to increase tobacco taxation, and has legislated for smoke-free 
environments. The utility and effectiveness of the tobacco control programme are 
monitored on a regular basis with surveys (Tobias, Cavana, & Bloomfield, 2010). 
Self-reported results from the 1996-1997 Census revealed that 25% of the New 
Zealand adult population identified themselves as daily smokers, but by 2012-
2013 this rate declined to 18%. According to Turia (2014), the decline in tobacco 
consumption and prevalence can be credited to the tobacco control programme. 
As mentioned above, this programme consists of many components, and it 
appears that tobacco-related taxes play the biggest role in the rapid decline in 
smoking prevalence and consumption (Ministry of Health, 2014). 
Tobacco price increases. 
Taxation on cigarettes is extensively endorsed as an effective population-
based strategy, and in 2013, the New Zealand government raised the taxes for 
tobacco to one of the highest levels in the world (Esther & Ajmal, 2013). 
Although the underlying aim of taxation may be to influence current smokers to 
smoke less, and to prevent non-smokers from taking up smoking, individuals 
respond to taxation in a number of ways. Data compiled from surveys on the 
effects of tobacco price increases reveal that, while some individuals do quit either 
on their own or with the help of a Quitline, others will buy cigarettes in bulk to 
save money (Zhu, Lee, Zhuang, Gamst, & Wolfson, 2012). Alternatively, they 
might turn to substitutes, such as buying cheaper cigarettes, or the taxation may 
have no effect on the smoker whatsoever, and as a result, they are subject to 
financial stress and hardships (Guillaumier, et al., 2014). Data taken on tax-
provoked price increases in 1991, 1998, and 2001 reveal that following cigarette 
price increases, sales declined (Laugesen, 2002). A New Zealand study following 
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a tobacco price increase in 2010 and 2011 revealed that the price increase 
influenced a large percentage of individuals of low socio-economic status to quit 
smoking. However, the relapse rate for this group was high, and those individuals 
who did not quit successfully managed by reducing their cigarette consumption or 
by switching to cheaper brands. Based on these findings, Kimura (2012) proposed 
for a steeper tax increase. 
Smoke-free legislation. 
Smokers are given incentive and support to quit smoking, with numerous 
laws that now restrict people from smoking in public places. In 1990, legislation 
to prohibit smoking in indoor offices was enforced and New Zealand was the first 
in the world to do so. In 2003, this act was revised, and the indoor environments 
list was made to include all work settings, including licenced premises, and public 
settings (Kring, Johnson, Davison, & Neale, 2012; Ministry of Health, 2015).  
Strong evidence exists in favour of smoke-free policies, particularly for an 
improved air quality, and a lessened exposure to second-hand smoke. The success 
of this policy is primarily due to the high level of support and compliance with the 
smoke-free legislation, by key stakeholders and the public. The smoke-free 
legislation also increases smokers’ level of motivation to quit smoking and 
decreases socially prompted smoking (Ministry of Health, 2006). Although, the 
effects of smoke-free legislation at the population level are unclear due to 
methodological issues, such as uncertainty for compliance for the enforcement of 
the Smoke-free Environments Amendment Act (Edwards, et al., 2006). 
Pharmacotherapy. 
Under the clinical practice guidelines, pharmacotherapies are considered 
first-line smoking services (Zhu, Lee, Zhuang, Gamst, & Wolfson, 2012).  The 
12 
 
three key forms of available medication include NRT (nicotine replacement 
therapy), bupropion, and varenicline.  
Nicotine Replacement Therapy (NRT). 
Ucar and colleagues (2014) evaluated the effectiveness of pharmacologic 
therapies and found that NRT was the most effective pharmacologic tool for 
smoking cessation (Jha, et al., 2006). NRT encompasses a range of products, such 
as nicotine patches, nicotine spray, nicotine gum, nicotine lozenges, and e-
cigarettes. With the exception of the inhalers and the nasal spray, all other NRT 
forms can be purchased over the counter, providing individuals who want to quit 
freedom to select the type of tool they would like to use (Perkins, Conklin, & 
Levine, 2008). Nicotine replacement targets smoking cessation through releasing 
small doses of nicotine into the body, and through allowing the individual to 
transition from larger to smaller doses, until they are no longer nicotine 
dependent.  
A disadvantage of NRT is that it does not cater to individuals with low 
socioeconomic status, who are high-risk populations. The cost for NRT may be 
reduced with a Quitcard subscription, offered through Quitline, however not 
everyone has access to this subscription, and therefore a combination of a 
Quitcard and a Quitline subscription are required, as opposed to a sole 
intervention (The QuitGroup, 2015). Each of the nicotine replacement therapy 
products have probable side effects, such as sleep disturbances, nausea, and light-
headedness (Brannon & Feist, 2009). A major implication for NRT is that it may 
serve as a mere replacement for nicotine, thus making it easy to overdose on this 
product and become addicted (West & Shiffman, 2007).  
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Nicotine-free inhalators. 
Nicotine-free inhalators act as a replacement for smoking cues and rituals, 
through serving as a coping mechanism for hand-to-mouth actions. These 
inhalators are particularly useful for individuals for whom tobacco use is 
influenced by behavioural characteristics (Caponnetto, et al., 2011).  
E-cigarettes. 
The health consequences linked with traditional cigarettes gave rise to the 
introduction of e-cigarettes, as recreational substitutes for cigarettes. E-cigarettes 
produce vapour made from nicotine-infused liquid, providing smokers with the 
sensation of smoking and satisfying their need for nicotine (Babin & Harris, 2015; 
Dockrell, Morison, Bauld, & McNeill, 2013; Wagener, Slegel, & Borrelll, 2012).   
Unlike normal cigarettes, e-cigarettes are not harmful to bystanders and 
they do not let off smells (Shaw, 2014). The potential harms of e-cigarettes have 
been subject to debate, with its increasing popularity, as little literature is 
available on e-cigarettes. A counter argument is that individuals who use e-
cigarettes do not give up smoking, as these individuals still crave nicotine (Shaw, 
2014). It has been suggested that e-cigarettes encourage continued smoking, as 
nicotine may continue to be consumed in places where regular smoking is banned 
(Hales, 2014). The United States Food and Drug Administration (FDA) is yet to 
approve this substance as it contains unknown carcinogens, and due to poor 
manufacturing practices used in the development of e-cigarettes (Odum, O'Dell, & 
Schepers, 2012). Consequently, many cities in the U.S have placed restrictions on 
where the product can be used (Babin & Harris, 2015).  
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Pharmacologic (no nicotine) Bupropion. 
Bupropion is an antidepressant medication that is available on 
prescription. In recent years, this medicine has been licensed by the FDA to be 
used for smoking cessation (Lewis, 2010). It is hypothesised that bupropion 
inhibits dopamine reuptake in the brain, particularly the reward centre which is 
also known as the mesolimbic dopamine system (Jorenby et al., 2006).  
 Evidence suggests that the key role of bupropion is to improve 
dopaminergic and noradrenergic activity, which is most commonly experienced 
by individuals who smoke nicotine. These activities are of importance as both 
norepinephrine and dopamine play a vital role in the mediation of withdrawal 
symptoms such as negative affect and irritability. Bupropion medication then 
works to attenuate these symptoms (Perkins, Conklin, & Levine, 2008), as it 
works to mimic the nicotinic properties of noradrenaline and dopamine. Through 
provoking nicotinic receptors, bupropion may prevent relapse (Warner & Shoaib, 
2006). However, according to Warner and Shoaib (2005), the exact mechanistic 
action of bupropion in smoking cessation is unknown, as a result, health 
practitioners are less likely to recommend bupropion to patients and the general 
public (Anczak & Nogler, 2003). Additionally, bupropion has only been shown to 
help relieve withdrawal symptoms, and does not work to stop smoking (Wikes, 
2008). 
Varenciline (Champix, Chantix). 
Varenciline is the most current pharmacological intervention, introduced 
in 2006 (Joernby, et al., 2006). The fixed action of varenciline is to stimulate 
nicotinic receptors, with a particular focus on the α4β2 nicotinic acetylcholine 
receptor. Evidence suggests that the α4β2 subtype is a key mediator of nicotine 
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dependence, due to its dependence-generating properties. Through its 
antagonising properties, hypothetically, this medicine offers relief to cigarette 
craving, and to nicotine withdrawal (Jorenby, et al., 2006).  
Joernby and colleagues (2006) compared the effectiveness of varenicline 
with a placebo, and with bupropion. It was noted that varenicline was an effective 
treatment for smoking cessation, in both the long and short-term, and its efficacy 
exceeded placebo and other pharmacologic treatments such as bupropion. 
However, a comparative study examining the risk of suicide, depression, and self-
harm behaviours associated with NRT, varenciline, and bupropion, revealed that 
the relative risk for these behaviours were significantly higher for those taking 
varenciline. In a sample of 2925, 90% of the individuals allocated to varenciline 
condition reported negative feelings (Bland, 2012). 
Perkins, Conklin, and Levine (2008) suggest that counselling should be 
used alongside these first-line medications, as counselling has the potential to 
address psychological issues associated with smoking abstinence, as well as 
maintaining smoking abstinence in the absence of medication.  
Complementary and alternative interventions. 
Acupuncture. 
Acupuncture entails inserting fine needles into the body. Acupuncture can 
be used to reduce the desire to smoke, as it has the potential to affect the taste 
associated with tobacco. Acupuncture can also be used to reduce withdrawal 
symptoms that follow abstinence (He, Medbo, & Hostmark, 2001).  White, 
Rampes, Liu, Stead, and Campbell (2014) evaluated the effects of acupuncture 
compared to treatments such as NRT, advice, counselling, and sham treatments. 
Sham treatments use one of two key techniques, dummy needles or needles that 
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have no active effect. Overall, inconsistent evidence was found for the feasibility 
of acupuncture and related therapies, although in the short term these techniques 
are better than no treatment. It was also found that acupuncture was less effective 
than NRT, and there was no evidence to show that acupuncture was a superior 
alternative to counselling (White, Rampes, Liu, Stead, & Campbell, 2014).  
Hypnotherapy. 
Hypnotherapy works to increase an individual’s concentration and acts on 
their fundamental urges through strengthening the client’s will to quit and or 
deteriorating their desire to smoke. The primary aim of hypnosis is to induce 
relaxation and modify the state of consciousness for clients. A disadvantage of 
this intervention is that there is no single standardised method for delivering 
hypnotherapy for smoking cessation, making it problematic to compare and 
contrast the efficacy of this treatment (Blomgren, 2003).  
A Cochrane review carried out by Barnes, Dong, McRobbie, Mehta, and 
Stead (2010) concluded that the evidence for the feasibility of hypnotherapy was 
conflicting, and little effect was found when hypnotherapy was compared to 
psychological treatments (White, Rampes, Liu, Stead, & Campbell, 2014).  
Quitlines. 
A number of factors attract individuals to use Quitlines, such as 
anonymity, privacy, convenience, and cost-effectiveness of these interventions. 
Additionally, counselling sessions can be easily organised, and the anonymous 
nature allows the client to open up faster and it helps the counsellor in gaining an 
accurate picture of the client. According to Lichtenstein, Zhu, and Tedeschi 
(2010), Quitlines appeal to members of the public who are usually underserved. 
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However, Quitlines are not effective as sole interventions and require 
collaborative action (Lichtenstein, Zhu, & Tedeschi, 2010). 
Aversion therapy. 
Aversion therapy is a treatment in which pleasurable stimuli associated 
with cigarettes (smoking) are paired with unpleasant stimuli (nausea or shock), 
and this pairing works to overwhelm urges to smoke. Hajek and Stead (2000) 
reviewed 24 studies that compared the effects of aversive therapy. Insufficient 
evidence in support for the efficacy of this technique was found, and no 
recommended dose levels were established (Hajek, & Stead, 2000). 
Smartphone delivered interventions. 
The dawn of new technology facilitates access to many more 
interventions, through modes of delivery such as internet access and smartphones. 
In 2014, 252 smartphone applications (apps) targeting smoking cessation were 
identified on the apple market and 148 were identified on the android market.  
Abroms, Padmanabhan, Thaweethai, and Phillips (2011) suggested that current 
apps could be improved through integration with evidence-based practice. 
Research conducted on iPhone smoking cessation apps revealed that, in 2009, the 
level of adherence to the apps was quite low.  The most downloaded apps had 
lower adherence scores compared to other quitting smoking apps that were less 
frequently downloaded (Abroms, Padmanabhan, Thaweethai, & Phillips, 2011; 
Roberts, Kerr, & Smith, 2013). 
A survey conducted in 2013 revealed that, in New Zealand, 59% of the 
adult population either had access to or owned a smartphone. For individuals in 
the 18-54 years age group, 71% had access to or ownership of a smartphone (Patel 
et al., 2015).  
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The use of mobile phones to deliver smoking cessation leads to double the 
quit rate for smoking (Abroms, Padmanabhan, Thaweethai, & Phillips, 2011). 
This is partly due to mobile phones being easily accessible (within arm’s reach), 
versatile, and universal. The privacy that comes with smoking cessation 
programmes on smartphones may also play a role in the high quit rates accounted 
by smartphone cessation programmes (Abroms, Padmanabhan, Thaweethai, & 
Phillips, 2011; Whittaker, et al., 2012).  
STOMP. 
STOMP is a text-to-quit intervention in which smokers who want to quit 
receive automated messages for 4 weeks, five messages a day. Within this 
intervention, individuals are taught behaviour-change techniques, such as access 
to distractions such as trivia and quizzes to avoid cravings to smoke, users are also 
given the opportunity to text STOMP for feedback on how to cope with their 
craving to smoke (Kong, Ells, Camenga, & Krishnan-Sarin, 2014). STOMP is 
effective in providing short-term smoke-free outcomes but not long-term 
outcomes, thus, relapse rates for this intervention are high (Bramley, Riddell, 
Whittaker, Corbett, & Lin, 2005).  
WebQuit®. 
In 2010, Bricker et al. compared a web-based ACT intervention for 
smoking cessation called WebQuit® with another web-based intervention called 
smokefree.gov. WebQuit® is a self-paced 8-part package and includes 
pharmacotherapy advice, social support, and planning advice for quitting. The 
comparison intervention, smokefree.gov, was the most widely used website at the 
time. Bricker et al. reported that participants in the WebQuit® condition engaged 
with WebQuit® at higher rates and were more satisfied with the website. 
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Furthermore, data taken at a 3-month follow-up revealed that 23% of the 
individuals from the WebQuit® condition had given up smoking for a period of at 
least 30 days, whereas for the smoke-free condition the quit rate was 10%. 
Increases in acceptance levels were also seen for individuals in the WebQuit® 
group.  
Behavioural interventions. 
Behavioural interventions are designed to help guide successful quit 
attempts through incorporating advice, encouragement, and discussion. 
Behavioural techniques commonly address key aspects of smoking cessation such 
as self-efficacy and motivation (Roberts, Kerr, & Smith, 2013). Fiore and 
colleagues (2008) suggested that behavioural treatments are effective for tobacco 
cessation and thus, should be the primary treatment for smoking cessation.  
Cognitive Behavioural Therapy (CBT). 
Currently, the most frequently used (gold standard) behavioural 
intervention is Cognitive Behavioural Therapy (CBT). The underlying goal of 
CBT is to teach individuals the skills required to cope with internal and external 
cues to smoke, with internal cues being cravings and external cues being viewing 
other people smoke cigarettes. CBT uses strategies such as helping those who 
smoke to reduce or avoid internal cues to smoke (Hernandez-Lopez, Bricker, 
Montesinos, Luciano, & Roales-Nieto, 2009).  
Acceptance and Commitment Therapy (ACT). 
Acceptance and Commitment Therapy (ACT) is a recent innovation to 
behaviour therapy and has grown out of the behavioural tradition. The foundation 
of ACT is formulated on a functional contextualism program of Relational Frame 
Theory (RFT).  RFT offers a theoretical account of human language, cognition, 
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and basic research. The underpinnings of ACT are based on this very account 
(Harris, 2009), however ACT takes a new and improved path, as instead it 
encompasses human language to take a fresh look at human suffering and pain 
(Hayes, 2004) through aiming to change the function and the context of the 
problem (Beharry, 2008). 
The primary therapeutic goal of ACT is to increase psychological 
flexibility, defined as contacting the present moment, and successfully preserving 
or varying behaviour in the provision of achieving valued outcomes. This goal is 
achieved through decreasing experiential avoidance (EA), the process of 
suppressing and avoiding unwanted feelings, sensations, thoughts, and other 
secretive events (Bach & Moran, 2008). EA has short-term positive rewards and is 
reinforced from an early age. Also given the link of EA with language, individuals 
are more likely to engage in it, as through language relations are formed between 
language and thoughts (Hayes et al., 1996). 
 Under an ACT framework, clients are commended to not fight or avoid 
challenges (which is the normal approach), and they are instead taught to embrace 
and accept their difficulties, whilst accepting their discomfort in life, and acting 
on their fundamental values (Hayes, Luoma, Bond, Masuda, & Lillis, 2006). Also 
under an ACT framework, mindfulness, and value-congruent living is given 
preference over symptom reduction, as the aim is to change the person’s 
relationship with their symptoms so that they can live a better life (Harris, 2009).  
ACT can be understood and defined by six core therapeutic processes. 
These six core processes are interrelated and together they make a 6-faceted 
diamond, called psychological flexibility (Bach & Moran, 2008; Hayes et al., 
2006). 
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Acceptance refers to a readiness to experience without any defence; this 
entails making room for urges, emotions, painful feelings and sensations, rather 
than resisting them  (Harris, 2009). With reference to smoking cessation, an ACT 
therapist would support the client to accept previously avoided stimuli to quit 
smoking (Gifford, et al., 2004). 
Defusion is a technique used to decrease the unhelpful effects of cognition 
and language. Defusion refers to detaching images, memories, and thoughts of 
oneself (Harris, 2009). This process is important, as it allows clients to act in 
accordance with their values, and their environment (Bach & Moran, 2008). An 
ACT therapist would teach individuals defusion techniques such as the 
identification of internal and external cues associated with smoking, and strategies 
to deal with and manage these triggers. Clients would also be taught to see in 
actuality, in that they would see thoughts to smoke as mere thoughts, rather than 
as reasons to smoke cigarettes (Hernandez-Lopez, Bricker, Montesinos, Luciano, 
& Roales-Nieto, 2009). 
Contact with the present moment refers to the act of becoming aware of 
the surroundings and events happening around the individual’s body (Bach & 
Moran, 2008).  
Committed action is when behaviour is in line with the individual’s chosen 
values. An example of this would be an individual engaging in overt responses 
that are both important to them and hold clinical relevance, these overt responses 
aid them to bring their life back on track  (Bach & Moran, 2008). An ACT 
therapist would support the client to commit to their identified values, e.g. a 
smoke-free lifestyle (Hernandez-Lopez, Bricker, Montesinos, Luciano, & Roales-
Nieto, 2009) and act on the identified values. 
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Self-as-context refers to pure awareness, in that there are two distinct 
elements to our minds, the observing self and the thinking self (Harris, 2009). 
When looking at the ‘self’ as a perspective, three distinct categories must be 
examined; self-as-content, self-as-context, and self-as-process (Bach & Moran, 
2008).  
Values serve as chosen life directions (Bach & Moran, 2008). Values also 
provide the best context for a person, as they allow the person to step outside of 
rigid and refined roles and live freely, without being controlled by culture (Hayes 
& Smith, 2009).  An ACT therapist would support the client in identifying values 
that align with their personal choices of a smoke-free and meaningful lifestyle, 
such as choosing a quit date, and selecting a method to quit smoking (Hernandez-
Lopez, Bricker, Montesinos, Luciano, & Roales-Nieto, 2009).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
ACT is an ideal treatment for individuals for whom tobacco use is 
maintained by a struggle to both avoid and modify negative stimuli, which in this 
case would be withdrawal symptoms. Evidence suggests that ‘avoidance’ provides 
the smoker with negative reinforcement, which then serves to maintain nicotine 
dependence (Gifford, et al., 2004). 
To summarise, the ‘acceptance’ component of ACT, makes efforts to help 
individuals to identify and accept inner triggers to smoke, and not avoid 
withdrawal symptoms. The ‘commitment’ component, emphasises the articulation 
of personal values and committing to stop smoking (Mak & Loke, 2015). 
According to Herbert and Gaudiano (2005) under an ACT framework, low 
acceptance of internal experiences is the issue, as low acceptance is equivalent to 
high experiential avoidance. Those with low acceptance levels feel distressed 
when aroused and will attempt to reduce and avoid internal experiences. These 
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negative processes then lead to a disruption in behaviour, as such techniques 
disrupt one's ability to live a quality life. Also taking an ACT-based approach 
Gifford et al. (2004) accentuates that the underlying mechanism for smoking is 
negatively reinforced avoidance. Under an ACT-based approach, the issue is the 
way in which the individual responds to their internal states. It was found that 
these very individual responses were predictive of smoking cessation outcomes, 
with a negative response, inflexibility and withdrawal symptoms acting as 
predictors. 
Usefulness of ACT. 
With ACT being a recent innovation, evidence on the usefulness of ACT 
is still growing, and thus very few studies have examined the effects of ACT on 
smoking cessation. ACT has shown promise for treatment of many psychological 
disorders, such as depression, anxiety, substance abuse, psychosis, stress, and 
chronic pain (Hernandez-Lopez, Bricker, Montesinos, Luciano, & Roales-Nieto, 
2009). Though these disorders differ in their functions, they all share a common 
feature being that the individuals with these disorders all try to reduce or control 
private aversive events, such as pain, cravings, anxiety, sadness, and delusions. 
Evidence suggests that this attempt to control may work in the short run; however, 
it is not a long-term alternative (Hernandez-Lopez, Bricker, Montesinos, Luciano, 
& Roales-Nieto, 2009). 
ACT is suitable for wide range of populations and conditions. For 
instance; it can be suitable for conditions such as depression, social phobia, 
anxiety, chronic pain, drug use, weight control, workplace stress, smoking 
cessation, and much more (Harris, 2009). 
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Lopez et al. (2009) used a quasi-experimental design, where, in the ACT 
condition, the exercises used by clients concentrated on the individuals’ 
motivations and values to quit smoking, on enhancing the willingness to 
experience urges to smoke, and on internal distress associated with being smoke-
free. Forty-three individuals were allocated to the ACT group, and 38 individuals 
to the comparison condition (CBT). Each of the two treatments was delivered, 
once a week for 7 weeks, and each session lasted for 90 min. The authors 
concluded that ACT was just as feasible as CBT as a treatment for smoking 
cessation. ACT participants were satisfied with the treatment, attended sessions, 
practised the ACT techniques taught during treatment sessions regularly, and 
found the effects of the treatment satisfying. Although the CBT condition revealed 
similar treatment effects, it was found that the ACT condition produced a higher 
abstinence rate, which was 5.13 times higher than the CBT abstinence rate 
(Hernandez-Lopez, Bricker, Montesinos, Luciano, & Roales-Nieto, 2009).  
In a CBT and ACT analysis it was noted that individuals who were 
allocated to the CBT condition displayed greater relapse rates, and it was also 
found that CBT was not as cost-effective as the comparison condition, ACT 
(Hernandez-Lopez, Bricker, Montesinos, Luciano, & Roales-Nieto, 2009). 
Gifford et al. (2004) compared the effectiveness of ACT with NRT 
(Nicotine replacement therapy). They allocated 76 nicotine-dependent individuals 
to one of two treatment conditions (ACT vs. NRT). In spite of there being no 
differences between the people assigned to the two conditions at posttreatment, 
individuals who were in the ACT condition showed better long-term outcomes at 
a 1-year follow-up and enhancements were also revealed in participants’ 
acceptance-related skills.  
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SmartQuit™. 
SmartQuit™ is a mobile phone application based on Acceptance and 
Commitment Therapy principles, and compares well to all other smoking 
cessation apps. SmartQuit™ includes eight effective activities that provide 
techniques for dealing with urges to smoke cigarettes, other features of the app 
include; an urge counter, a counter for tracking urges that have passed, a calendar, 
an anytime coaching section, and a quit plan. Features such as accessibility, ease 
of use, use of evidence-based practice, and absence of physiological side effects, 
sets this app apart from others. However, further research is required to determine 
its efficacy. The underlying goal of SmartQuit™ is to teach individuals techniques 
to accept their urges, and over time, these urges fade. The programme begins by 
introducing users to a quit plan, which is completed before starting the activities 
within the app. This quit plan can be updated at any time, and it contains many 
personal questions which provide a basic understanding of the user’s behaviours 
and attitudes toward smoking, along with their stress levels, and the amounts of 
money spent on smoking both daily and per packet. Following completion of the 
quit plan, the user tracks their urges to smoke on the app on a daily basis. 
Alongside tracking urges, the user completes daily exercises. It is recommended 
that these daily exercises be completed more than once before moving to the next 
activity. There are total of eight exercises to complete and each time one activity 
is completed, another is unlocked.  For every 10 urges recorded and for every 
activity completed, a badge is received.  The app also includes a section for 
anytime coaching which includes stories of others, tips to manage urges, an ‘ask a 
coach’ section and many more areas. The quit date for smoking cessation can be 
reset before approaching the quit date, and after having quit, as a notification is 
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sent asking how the quit went and, if unsuccessful, the user is given the option to 
reset the date and try again. 
QuitGuide®. 
QuitGuide® was developed by smokfree.gov and released in 2010. This 
app can be accessed via a smartphone or computer and is free of charge, making it 
accessible and transparent in nature (ICF international, 2015). QuitGuide® is 
similar to SmartQuit™, which also has a counter for recording cravings to smoke, 
and provides guidance and strategies for how to both become smoke-free and 
maintain it, as does SmartQuit™ in the personalised quit plan. A factor that sets 
this app apart from SmartQuit™ is that QuitGuide® also features a mood tool, 
which is used when cravings are experienced, and the tips on the mood tool are 
used to manage the smoker’s mood when they are experiencing a craving (ICF 
international, 2015).  
Many features distinguish SmartQuit™ from QuitGuide®. For instance, 
QuitGuide® provides smokers with tips and skills to escape cravings to smoke 
cigarettes, these can be possibilities for replacement behaviours or keeping busy, 
information on FDA- approved medications, and encouragement for the smoker to 
dig deep and write a list of reasons for why they want to quit. Features these apps 
share in common include the widely available skills and tips for how to deal with 
slip-ups, and the feature of connecting to social communities for extra support, 
e.g. to share experiences and to read others’ stories (Bricker et al., 2014).  
Bricker et al. (2014) evaluated the effectiveness of SmartQuit™ with 
QuitGuide®, with a sample of 196 smokers randomly allocated to each of the 
conditions. Bricker and colleagues reported that the SmartQuit™ app was opened 
an average of 37.2 times, whereas, QuitGuide® participants only opened the 
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application 15.2 times. For participants assigned to the SmartQuit™ condition, 
acceptance of cravings increased after using the SmartQuit™.  Results obtained 
from Bricker and colleagues pilot study demonstrated lower levels of adherence 
with the QuitGuide® app (Zeng, Vilardaga, Heffner, & Bricker, 2015).When 
compared with QuitGuide® (developed by the National Cancer Institute), 
individuals using SmartQuit™ accessed the app at significantly higher rates than 
those individuals who were in the QuitGuide® condition. Another major finding 
was that the quit rates were higher for individuals in the SmartQuit™ condition, 
which were 13%, whereas the quit rates for those assigned to the QuitGuide® 
condition were 8% (Zeng, Vilardaga, Heffner, & Bricker, 2015). 
The Current Study 
Gifford et al. (2011) suggest that, although most people want to quit 
smoking, only 50% try to quit and only a further 2.5% are successful every year. 
These statistics suggest that smoking cessation interventions with a new focus are 
required. While the already present smoking cessation interventions look to 
address the high prevalence of smoking, they do not fully incorporate factors such 
as evidence-based practice, accessibility, compliance, active support, and long-
term smoke-free outcomes.  
Using a single-subject, A-B-A-C design, I aimed to investigate the 
effectiveness of the SmartQuit™ app, based on ACT principles, with a New 
Zealand sample. I also aimed to determine whether scores obtained on the 
Commitment to Quit Scale would predict smoking outcomes at post-intervention, 
and follow-up phases. I expected that that participants would smoke fewer 
cigarettes after the intervention. Secondly, I hypothesised that those participants 
who obtained high scores on the Commitment to Quit Scale would have better 
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chances for smoking noticeably less than what they did during the baseline phase. 
Thirdly, as SmartQuit™ is ACT based, and the goal of ACT is to increase 
acceptance and willingness of internal experiences, I expected that acceptance 
levels (embracing internal experiences, e.g. thoughts, and feelings) would 
increase, and experiential avoidance (avoiding unwanted internal experiences) 
would decrease. Examining acceptance levels is of importance as the literature 
reviewed above shows that higher acceptance increases quality of life. Finally, I 
measured cravings, to see if they would change after the intervention. 
 A small-N, within-subjects design was used in this study. I chose this design, 
firstly because this meant that all subjects received the intervention.  Secondly, 
inter-subject variability was reduced, as each subject served as his or her own 
control. Thirdly, this research design allowed repeated measures at baseline and 
post-intervention, thus providing stable assessments. Fourthly, there was no need 
for group percentages as the success of the intervention could be determined 
through individual characteristics (Butler, Sargisson, & Elliffe, 2011). Finally, this 
design allowed for flexibility in time, meaning that participants could work 
through the intervention at their own pace and take as much time as they needed. 
Method 
Participants 
I recruited participants in response to fliers (Appendix A). I posted fliers 
primarily on social media, in newspapers, and in various tertiary institutions in the 
Waikato and Bay of Plenty areas. I also gave fliers and information sheets which 
described the research to various medical centres (Appendix B), and health 
practitioners were asked to recommend the SmartQuit™ programme to 
individuals wanting to quit smoking. The Heaviness of Smoking Index (HSI) 
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(Appendix C) was used to screen participants for the current study, and one 
participant was excluded because they obtained a score of less than four on this 
measure (a score of less than four falls in the no or little dependence range). A 
further two more individuals were excluded because they were using other 
smoking cessation tools in an attempt to stop smoking. These individuals were 
excluded so that the interventions they were using would not interfere with the 
intervention offered in the current study. Each participant was provided 6 months’ 
free access to SmartQuit™, which usually costs $60 when purchased from the app 
store.  The study procedures gained ethical approval from the University of 
Waikato School of Psychology Ethics Committee (ethics approval number 
#15:40).   
I determined selection and suitability into the current study using an 
eligibility survey (Appendix D). The requirements to take part in the study were; 
1) participants had to be at least 18 years of age; 2) had smoked at least 10 
cigarettes per day in the past 12 months; 3) had a score of four or higher on the 
(HSI); 4) wanted to quit smoking in the near future; 5) had access to a 
smartphone, that was compatible with the SmartQuit™ programme; and 6) they 
consented to not use any other interventions or medication throughout the 
intervention phase. Individuals were excluded if they were 1) under the age of 18 
years; 2) obtained a score of less than 4 on the HSI; 3) presently seeking or 
undergoing psychological treatment e.g Cognitive Behavioural Therapy; 4) a non-
English speaker; 5) using nicotine replacement products in an attempt to quit 
smoking; and 6) no access to a smartphone. Twenty-eight individuals expressed 
an interest in taking part in the current study. However, thirteen out of this 28 
either declined to take part or did not respond further.  Thirteen completed the 
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screening survey, and three were excluded for not meeting the study criteria. Ten 
individuals participated in the study (they did not receive course credit or any 
compensation for taking part) Five of the participants were female, and five were 
male. Participant ages varied (Table 1) and ranged from 25 to 54. 
Table 1 
Summary of Demographic Details for Participants Who Fully Completed the 
Study 
 
ID Sex Age Ethnicity 
Daily 
cigarette 
intake 
Number of 
years 
smoking 
Number 
of quit 
attempts 
 
1 M 33-44 Māori 20 5 years 3+ 
 
2 M 33-44 European/Pakeha 25 21 years 3 
 
3 M 33-44 European/Pakeha 10 to 20 11 years 10 
 
4 M 33-44 European/Pakeha 20 30 years 2 
 
5 M 45-54 European Indian 20 17 years 3 
 
6 F 45-54 Māori 10 30 years 10 
 
7 F 25-33 European/Pakeha 10 to 20 11-12 years 2 
 
8 F 25-33 European/Pakeha 20 12 years 1 
 
9 F 33-44 European/Pakeha 8 to 14 20 years 8 
 
10 F 33-44 European/Pakeha 10 30 years 5+  
 
Apparatus 
I provided participants with an information sheet, an eligibility survey, a 
consent form, and a series of questionnaires. These questionnaires were completed 
in the baseline phase and again at the post-intervention phase. I also gave 
participants notebook-sized journals, to record daily counts for cigarettes and 
cravings to smoke. To gain full access to the app used in this study, participants 
were provided with individual and unidentifiable login details along with a 
demonstration of how to use the smartphone app. 
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Measures 
The Heaviness of Smoking Index (HSI). 
The Heaviness of Smoking Index (HSI) is a 2-item measure, based on the 
FTND (Fagerström test for Nicotine Dependence) (Appendix C). Evidence 
suggests that these two items hold more predictive power in terms of quitting 
smoking behaviours, than the other items included in the FTND (Borland, Yong, 
O'Connor, Hyland, & Thompson, 2010). The summing of the two items provides 
a total score on this measure, with a score of four or higher being suggestive of 
high nicotine dependence. For the other category which is the heavy smoking 
category, the number of cigarettes per day must be 20 or more (Lim, et al., 2012). 
Internal consistency was evaluated by Etter (2005) and Cronbach alpha 
coefficients of 0.63 were reported. 
The Cigarette Dependence Scale (CDS). 
To assess nicotine dependence, I used the Cigarette Dependence Scale 
(CDS) (Appendix E). The CDS is a 9-item measure, which uses a 5-point Likert 
scale (Courvoisier & Etter, 2010). The scores on this scale range from 0-60, with 
higher scores on the CDS anticipating successful smoking cessation (Okuyemi, et 
al., 2007). The cut-off score for low cigarette dependence is a score of 12. The 
instruments covered in this measure are based on the definitions of dependence in 
the DSM-IV and the ICD-10 manual (Okuyemi, et al., 2007). The CDS has 
excellent reliability, demonstrated by its high internal consistency of .90 and 
moderately high test-retest reliability of r = .84 (Wittekind, Feist, Schneider, 
Mortiz, & Fritzsche, 2015). Etter (2008) compared the validity of the CDS with 
the Fagerström which is currently the most commonly used measure of nicotine 
dependence. Etter (2008) reported that the CDS had greater validity and reliability 
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when compared to the Fagerström. Etter also reported that the CDS had great 
internal consistency, greater content validity, and was a better predictor of 
withdrawal symptoms when compared to the Fagerström. Finally, it was noted 
that when compared to the Fagerström, the CDS was more sensitive to change 
over time.  
Commitment to Quitting Smoking Scale (CQSS). 
Motivation to quit smoking was a dependent variable in the current study, 
and without a strong motivation to quit, giving up smoking can be difficult. To 
assess this variable, I used the Commitment to Quitting Smoking Scale (CQSS) 
(Appendix F). The CQSS is an 8-item questionnaire and the items on this 
questionnaire are rated on a 5-point Likert scale, with one indicating strongly 
disagree and five indicating strongly agree. Scoring for this questionnaire is based 
on the total score and is calculated by summing the eight items (Kahler et 
al.,2007).  Kahler and colleagues (2007) observed the psychometric properties of 
the CQSS in a sample of heavy drinkers, and they noted that this measure had 
high test-retest reliability, avoided ceiling effects, and the construct and content 
validity of this measure were immune from changing over time (Etter, Houezec, 
& Perneger, 2003; Kahler, et al., 2007). Kahler and colleagues (2007) also noted 
that this measure had good internal consistency, demonstrated by the Cronbach 
alpha value of .91 (Kahler, et al., 2007). 
The Acceptance and Action Questionnaire (AAQ-2). 
Acceptance was a key variable in this study and was measured by the 
Acceptance and Action Questionnaire (AAQ-2) (Appendix G). The AAQ-2 is a 7-
item self-report questionnaire, designed to assess constructs such as experiential 
avoidance, acceptance, action, and immobility. This measure uses a 7-point Likert 
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scale to rate items, with one indicating never true and seven indicating always 
true. On this measure, a high score reveals excessive immobility and experiential 
avoidance and a low score reveals excessive action and acceptance (Ciarrochi & 
Bilich, 2006). The psychometric properties of this measure were evaluated by 
Bond et al. (2011), and this measure revealed good psychometric properties which 
were reflected by its good test-retest reliability of .81 for testing taking place at 3- 
and 12-month periods and also by its good validity and good reliability, reflected 
by the alpha coefficient value of .84. 
Design 
I used a single-subject, A-B-A-C design consisting of four phases, and 
each participant entered the study at different times. Phase A was the baseline 
phase, Phase B was the intervention phase, Phase A was the post-intervention 
phase, and Phase C were the follow-up phases. 
Procedure 
Pre-baseline. 
Individuals who wished to participate contacted me via email, and 
information sheets detailing the research aims and procedures (Appendix H) were 
sent to these individuals. I emailed eligibility surveys to those individuals who 
responded to the information sheet with an interest to take part in the study 
(Appendix D).  
Baseline (A). 
During this phase, I arranged a time and place to meet with those 
individuals who had met the study criteria, and during this meeting informed 
consent (Appendix I) was obtained and queries that participants had about the 
study were answered. Also during this meeting, I asked participants to complete a 
34 
 
demographic questionnaire (Appendix J), and three brief measures were 
administered; one measured the level of nicotine dependence, one measured 
motivation to quit, and the other measured acceptance and mindfulness levels.  
Cigarette dependence was assessed by the CDS (Appendix E), the level of 
motivation to quit was assessed by the CQSS (Appendix F), and acceptance levels 
were assessed with the AAQ (Appendix G). I also provided each participant with 
a mini wallet-sized notebook that could be conveniently carried around. I asked 
participants to continue with their normal smoking behaviour and respond to 
cravings as they usually would, to write down each time they smoked a cigarette, 
and each time they experienced a craving to smoke. Once participants started 
recording data they informed me, and from that date onwards at the end of each 
day, I text messaged each participant for their daily counts for cigarette intake and 
cravings to smoke, during this period.  Text messages were sent between 9pm and 
11pm each day. The baseline phase stopped once consistent patterns of cigarette 
smoking could be seen. The duration of this phase varied for each participant and 
took from 3-21 days.  
SmartQuit™ (intervention) (B).                
Once participants had completed the baseline phase, they were asked if 
they were ready to begin the intervention. Each participant was provided with 
instructions to download the SmartQuit™ app, along with an individual 
unidentifiable login ID and password, to gain full access to the app, free of 
charge. 
At the beginning of the programme, participants were provided with an 
introduction (Appendix K). Following this, participants completed a personalised 
quit plan, on the app, which could be updated at any stage of the programme 
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(Appendix L). Next participants used the urge tracker (Appendix M) to track their 
urges to smoke on a daily basis. Participants were also expected to complete daily 
exercises and there was a total of eight exercises to complete and each time one 
activity was completed, another was unlocked.  A badge was received for every 
10 urges recorded and for every completed activity. Once participants had 
completed all of the activities, then, the urge tracker was replaced with a tracker 
for counting urges that had passed (Appendix N). Participants used this tracker to 
count urges until they reached their quit date. If participants were not satisfied 
with the outcome of the intervention they were given the opportunity to try again 
(Appendix O), provided it was within six months of app access, as that was how 
long the app was available for. The length of this phase varied for each individual 
as it was dependent on how long it took participants to reach their quit date, and 
whether or not they reset their quit date. This period varied from two weeks up 
until 6 months. 
During the intervention phase, I avoided contact with the participants so as 
not to interfere with the app. That is, I intended to measure the effectiveness of the 
app on its own, without additional interventions. Additionally, to ensure the app 
was being used on a regular basis I was given access by 2morrow, Inc. to an 
administrator’s page (Appendix P), on which the activation date, progress and last 
activity of each participant could be viewed. I contacted those participants who 
had not accessed the app for a period of 7 days via text message or a phone call.  
Post-intervention phase (A). 
This phase took place immediately after completing the requirements of 
the app, which were completing all of the required activities and having reached 
the set quit date. This phase was similar to the baseline phase, as the notebook 
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was used again to record cigarette urges and/ or cravings and intake. Also during 
this phase, I met each participant, and I re-administered the CDS (Appendix E), 
CQSS (Appendix F) and the AAQ-2 (Appendix G). This was so that a comparison 
measure could be provided to compare whether SmartQuit™ had an effect on the 
frequency of cravings to smoke, the number of cigarettes smoked per day, and on 
acceptance and experiential avoidance levels. The duration of this phase took a 
maximum of 21 days, the period varying for each individual. Debriefing also took 
place within this phase, and participants were provided with the opportunity to ask 
any questions in regards to the nature of the research study.  
Follow-up phase (C). 
During this phase, participants were asked to complete two follow-up surveys 
(Appendix Q), which  measured satisfaction with treatment and smoking 
outcomes. These surveys included open and closed questions, and all participants 
were asked about their experience with the intervention. Surveys were sent via 
email, and the first follow-up survey was administered a month following the 
completion of the app and the second follow-up survey was administered a month 
after the first follow-up survey. 
Results 
Five male and five female particpants took part in this study. Participant 
characteristics are given in Table 1. The mean cigarette intake at baseline was 
16.61 per day (SD = 7.41). The number of years individuals had been smoking 
cigarettes ranged from 5-30 years, and all participants had attempted smoking 
cessation prior to the current study.  
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Daily Cigarette Consumption 
Figure 1 presents the daily cigarette intake for male participants taken at 
baseline and post-intervention plotted against the number of days for which 
cigarette intake was recorded.  
Figure 1 shows that all male participants had high levels of variable 
cigarette consumption during the baseline phase. During the post-intervention 
phase, cigarette consumption for Participants 1 and 3 had neither increased nor 
decreased. Cigarette consumption for Participants 2 and 5 during the post-
intervention phase decreased to zero, and a rapid decrease was seen for Participant 
4 during the post-intervention phase. Overall, all male participants displayed high 
levels of cigarette consumption during the baseline phase, and during the post-
intervention phase, three of the five male participants smoked notably less.  
In Figure 2, daily cigarette consumption for female participants taken at 
baseline and post-intervention was plotted against the number of days taken to 
reach stable smoking patterns. Data for two post-interventions was plotted in 
Figure 2 (as one participant, Participant 9, relapsed after the first post-intervention 
phase, so data was taken twice for this participant).  
Figure 2 shows that all female participants had high levels of cigarette 
consumption during the baseline phase, however, the number of cigarettes was 
lower than for male participants, both at the group and individual level. During 
the post-intervention phase, cigarette consumption levels for all female 
participants decreased by half and were close to zero. Consumption levels during 
the baseline phase were variable, and these levels were more stable during the 
post-intervention phase.  
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Also seen in Figure 2, Participant 9 successfully gave up smoking at post-
intervention, but then relapsed, and although Participants 9 and 10 were only 
smoking two cigarettes per day during the follow-up phase, they did not achieve 
smoking abstinence again.  
Intervention comparisons. 
To evaluate the effectiveness of the intervention on cigarette intake, I 
conducted a paired-sample t-test with mean cigarette consumption data taken 
across baseline and post-intervention phases for all participants. There was a 
significant decrease between the mean cigarette intake before, M = 16.61, 95% CI 
[11.47, 23.42], compared to after, M = 5.74, 95% CI [0.90, 11.85]; t(9) = 3.59, p = 
0.01, d = 1.47). The effect size of (d = 1.47) met Cohen’s (1988) criteria for a 
large effect (d = .80).  The significant difference indicates lower daily cigarette 
consumption at post-intervention. 
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Figure 1. Daily cigarette smoking intake for male participants at baseline and 
post-intervention, and average data points taken during the follow-up phases. 
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Figure 2. Daily cigarette smoking intake for female participants at baseline and 
post-intervention, and average data points taken during the follow-up phases. 
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Cravings to Smoke 
Figure 3 presents cravings to smoke cigarettes at baseline and post-
intervention for male participants.  Participant 1 reported low levels of cravings to 
smoke at baseline, and during the post-intervention, their cravings increased and 
were greater than the cravings reported during baseline. For Participant 3, 
cravings to smoke during the baseline phase were intermittent, and although no 
change in the frequency of cravings was seen during the post-intervention phase, 
their cravings fluctuated less during the baseline phase, when compared to 
cravings reported at post-intervention.  
Participants 2, 4, and 5 had variable cravings at baseline, and during the 
post-intervention phase, cravings to smoke for Participant 2 decreased slightly, 
and cravings to smoke for Participants 4 and 5 decreased by half.  Overall, Figure 
3 demonstrates that, during baseline, all participants had high levels of cravings to 
smoke, and following the intervention the frequency of cravings to smoke 
cigarettes decreased by almost half for three of the five male participants.    
Figure 4 shows cravings to smoke cigarettes at baseline and post-
intervention for female participants.  Figure 4 reveals that, during the baseline 
phase, all of the female participants experienced irregular cravings to smoke, and 
a low frequency of cravings to smoke cigarettes. At post-intervention and follow-
up, no obvious change was seen in cravings to smoke cigarettes.  
Intervention comparison. 
To evaluate the effectiveness of the intervention on the frequency of 
cravings to smoke cigarettes, I conducted a paired-sample t-test with mean 
cravings experienced across the baseline and post-intervention phases for all 
participants. There was a non-significant decrease between the mean level of 
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cravings to smoke before, M = 14.18, 95% CI [9.13, 19.23], compared to after, M 
= 9.19, 95% CI [5.44, 12.94]; t(9)= 0.187, p = 0.09, d = 0.68). The effect size for 
this analysis was large (Cohen1988). The lack of statistical significance can be 
explained by the low power.  
 
Figure 3. Cravings to smoke for male participants at baseline and post-
intervention, and average craving data points taken during follow-up phases. 
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Figure 4. Cravings to smoke for female participants at baseline and post-
intervention, and average craving data points taken during follow-up phases. 
 
Cigarette Dependence Scale Scores 
Figure 5 presents Cigarette Dependence Scale scores, for both female and 
male participants at baseline and post-intervention. CDS scores reflect low and 
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high levels of cigarette dependence, with higher scores on this measure indicating 
high dependence, and lower scores indicating low or no dependence. All 
participants had higher dependence scores during baseline, indicating greater 
cigarette dependence. Also seen in Figure 5, during the post-intervention phase, 
CDS scores decreased for all participants. For Participants 1, 6, 7, 3, 9, 4, and 5 
the decrease in CDS scores between the phases was small. In contrast, the post-
intervention CDS scores obtained by Participants 2, 8, and 10 were noticeably 
lower. Overall, Figure 5 shows that the mean CDS scores at baseline were 
relatively high, and during post-intervention these scores decreased, thus 
dependence decreased.  
A paired-sample t-test showed a significant difference between the mean 
CDS scores before, M = 49, 95% CI [46.27, 51.73], compared to after, M = 38.10, 
95% CI [31.08, 45.12]; t(9)= 3.72, p = 0.005, d = 2.76). The effect size for this 
analysis was large according to Cohen’s (1988) criteria. The decline in CDS 
scores indicates lower levels of cigarette dependence at post-intervention. 
 
Figure 5. Individual and mean scores obtained on the Cigarette Dependence Scale 
at baseline and post-intervention. 
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Commitment to Quitting Smoking  
Figure 6 presents the scores on the CQSS, for female and male participants 
at baseline and post-intervention. CQSS scores reflect the degree of commitment 
one has to quit smoking, with low scores on this measure indicating low 
commitment, and high scores indicating a high commitment to quit. Figure 6 
shows fluctuations in CQSS scores. During baseline, Participants 1, 6, 3, 4, and 5 
initially had obtained low scores on the CQSS, and during the post-intervention 
phase, CQSS scores for these participants increased. Also seen in Figure 6, 
Participants 2, 7 8, and 10 obtained low scores during the baseline phase, and 
higher scores on this measure during the post-intervention phase. 
A paired-sample t-test showed a non-significant difference between the 
mean CQSS scores before, M = 29.40, 95% CI [23.70, 35.10], compared to after, 
M = 27.50, 95% CI [21.64, 33.36]; t(9) = 0.72, p = 0.49, d = 0.23).  The effect size 
for this analysis was found to meet Cohen’s (1988) criteria for a small effect (d = 
.20). The decrease in CQSS scores indicates that individuals were less committed 
to quitting at post-intervention, and the difference was not statistically significant. 
Acknowledging the small sample size, I conducted a regression to 
determine whether scores obtained on the CQSS at baseline predicted the number 
of cigarettes smoked at post-intervention. A regression model showed that CQSS 
scores were not a significant predictor for cigarette intake after the intervention (F 
(1, 8) = .03, p = .86, R2 = .04). Given the small sample size, the chances for this 
regression being significant were unlikely, however, this regression still shows 
that with every increase of 1 in the commitment to quit score, participants are 
predicted to smoke 0.151 fewer cigarettes per day. 
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Figure 6. Individual and mean scores obtained on the Commitment to Quit Scale 
at baseline and post-intervention 
 
Acceptance 
Figure 7 presents the AAQ scores, for both female and male participants at 
baseline and post-intervention. AAQ scores reflect both psychological flexibility, 
and experiential avoidance, with low scores on this measure indicating high 
acceptance or psychological flexibility, and high scores indicating high levels of 
experiential avoidance. Figure 7 demonstrates that the scores obtained on this 
measure were variable. During the baseline phase, Participants 1, 2, 9, and 5 
obtained low scores, and, during the post-intervention phase, these participants 
obtained scores that exceeded their baseline scores on this measure. Also seen in 
Figure 7, Participants 6, 7, 8, 3, 4, and 10 had decreasing scores from baseline to 
post-intervention.   
A paired-sample t-test showed a non-significant difference between the 
mean AAQ scores before, M = 21.80, 95% CI [13.43, 30.17], compared to after, 
M = 20.90, 95% CI [13.71, 28.09]; t(9)= 0.31, p = 0.76), d = 0.07. The effect size 
for this analysis was found to meet Cohen’s (1988) criteria for a small effect (d = 
.20).  There was no correlation for AAQ scores with cigarettes smoked, and no 
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significant increases or decreases were seen for AAQ scores from first to last 
administration.  
 
Figure 7. Individual and mean scores obtained on the Acceptance and Action 
Questionnaire at baseline and post-intervention. 
 
The Effects of SmartQuit™ on Self-Report Measures  
A series of correlations were carried out to assess the relationship between 
all of the measures used in this study, and the difference between baseline and 
post-intervention for number of cigarettes smoked per day, number of cravings 
per day, CDS scores, CQSS scores, and AAQ scores are plotted in Table 2. 
Table 2 shows that the difference in cravings to smoke cigarettes is 
strongly related to the difference in cigarette intake, from baseline to post-
intervention, and as cravings to smoke increased, cigarette intake decreased. The 
difference in cigarette dependence levels was significantly related to the 
difference in cigarette intake, from baseline to post-intervention, and as cigarette 
dependence levels increased, cigarette intake decreased.  The difference in 
cigarette dependence levels were significantly related to the difference in cravings 
to smoke cigarettes from baseline to post-intervention, thus as cigarette 
dependence levels increased cravings to smoke also increased. A strong 
significant relation was found between the difference in CQSS and CDS scores 
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from baseline to post-intervention, so as commitment to quit levels increased 
cigarette dependence levels also increased. 
A non-significant relationship was found between the difference in 
cigarette intake and CQSS scores, between cigarette intake and AAQ scores, 
between cigarette intake and AAQ scores, between AAQ and CDS scores, 
between AAQ and CQSS scores, between CQSS scores and cravings to smoke, 
between AAQ scores and cravings to smoke. Demonstrating that each of these 
variables were unrelated, and had weak correlations. 
Table 2 
Correlations for all Self-Report Measures 
  Difference 
in intake 
Difference 
in cravings 
Difference 
in CDS 
Difference 
in CQSS 
Difference 
in AAQ 
Difference in intake 1 
    
Difference in 
cravings 
-0.72* 1 
   
Difference in CDS -0.77* 0.52** 1 
  
Difference in CQSS -0.38*** 0.14*** 0.83* 1 
 
Difference in AAQ 0.32*** -0.29*** 0.11*** 0.48*** 1 
 ***p< .005.  **p< .05.  *p< .10. 
Engagement and satisfaction with SmartQuit™ 
Table 3 depicts each participant’s overall engagement and progress with 
the smartphone app (SmartQuit™). The percentages in the progress column are 
based on the number of activities each participant completed. Those participants 
who completed all of the core requirements of the app gained a certificate of 
completion.  
Although each of the ten participants entered the post-intervention phase, 
not all participants completed all of the requirements of the app and therefore did 
not receive certification.  Table 3 shows that Participants 7, 8, 3, and 5 did not 
complete all of the activities provided in the app. However, two of these three 
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individuals successfully gave up smoking despite not completing all of the 
activities in the app.  
Table 3 reveals that Participants 2,7, and 5 were all successful in quitting 
smoking. Also seen in Table 3, the length of time spent using the app varied for 
all individuals. The shortest time was 2 weeks and the longest 16 weeks. Of the 
three individuals who quit smoking, Participant 2 used the app for two weeks, 
Participant 7 used the app for 16 weeks, and Participant 9 used the app for 7 
weeks.  
Table 3 
Summary of Details for Participant's Engagement with SmartQuit™ 
ID 
 
Progress Smoking status Time using SmartQuit™ 
1 
 
100% Smoking 8 weeks 
2 
 
100% Quit 2 weeks 
3 
 
45% Smoking 2 weeks 
4 
 
Certified Smoking 11 weeks 
5 
 
36% Quit 7 weeks 
6 
 
100% Smoking 4 weeks 
7 
 
86% Quit 16 weeks 
8 
 
95% E-cigarettes 2 weeks 
9 
 
Certified Quit 25 weeks 
10 
 
Certified Smoking 5 weeks 
 
Satisfaction (follow-up measured at one and two month periods). 
To assess smoking cessation, participants were invited via email to answer 
questions on their current smoking patterns. Eight of the ten participants 
completed two of the follow-up surveys, and two participants took part in neither 
of the follow-up phases.  
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During the follow-up phase, seven of the eight participants indicated that 
they had reset their quit date, the average time for resetting quit dates ranged 
between 1-4 times. Five of the eight participants relapsed at least once.  
At the first follow-up, three participants had quit smoking, and they had 
maintained abstinence at the second follow-up. Participant 1 and Participant 3 had 
shown no change in smoking at post-intervention, and showed similar smoking 
intake at both follow-ups, therefore, no change took place. The five individuals, 
participants 4,6,8,9, and 10 who showed reductions in smoking intake at post-
intervention but did not quit, reported low smoking rates at both follow-up phases 
as well, which suggests that these participants maintained their new smoking 
patterns. 
Of the eight participants who completed the follow-up phases, six 
indicated that the SmartQuit™ programme was appropriate for them, and 
Participants 1 and 3 disagreed or were indecisive about this statement, and these 
were the only two participants to show no change in smoking intake following the 
intervention.  
With the exception of Participant 3, all participants reported that their 
urges to smoke cigarettes had reduced, additionally one individual reported that 
their urges had ended completely. In contrast, Participant 3reported that their 
urges had increased. During the second follow-up phase, Participant 7 had 
successfully quit smoking, and as a result reported that their urges to smoke 
cigarettes had ended completely. 
With the exception of three participants, each participant was happy with 
their progress on the SmartQuit™ app. The three participants who were unhappy 
were Participants 3, 9, and 10. Participant 3 did not quit, and Participants 9 and 10 
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reported being unhappy as, although they were both smoking 2-3 cigarettes at 
post-intervention and during the follow-up phases, they expected to be smoking 
zero cigarettes but reported not being able to break the habit.  
In the follow-up surveys, participants were asked to comment on aspects 
that they preferred the most and the least preferred about the app. Aspects that 
encouraged participants to use the app were as follows. The ease of use of the app; 
the pictures and tips included in the app, the techniques provided to manage 
cravings, ownership and accountability of urges, notifications, acknowledging 
urges and tracking the urges, and allowing urges to pass and tracking these on the 
urges that have passed tracker. 
Least preferred aspects which triggered less app use included; the lack of 
clarity on when to complete each activity, the completion certificate not acting as 
a motivator or reward to continue app use or quit, the length of time it took to 
navigate through the app, that there was no way to track urges when driving or 
when phone was not in reach, the isolation (no friend or social aspect to feel 
connected), no locks on the exercises allowing them to be opened before having 
completed the previous exercises more than three times, and not being able to 
reset the urge counter and the urges-that-have-passed tracker. 
When participants were asked what triggered them to use the app, two key 
themes were revealed: 1) receiving notifications, and 2) needing to record urges. 
They reported that the best strategies learnt from SmartQuit™ were learning how 
to identify urges, learning to take ownership of urges, and controlling these urges. 
Participants found the river, tug of war, and the urge monster exercises (Appendix 
Q) as the most useful for dealing with urges.  
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Five participants commented that no improvements were needed, and 
those participants who commented that there was room for improvements 
suggested the addition of voice activation as a way to engage with the app, an 
incentive such as a badge for smoke-free days, a lock on the exercises so that 
exercises could only be unlocked after a day or so of practicing the previous 
exercise, a peer aspect to feel connected, and a diary of accountability. 
Individual Analyses 
During this study, two participants stopped using cigarettes, and used 
alternative products instead. At post-intervention Participant 8 changed to e-
cigarettes. At the second follow-up Participant 1 reported that they had changed to 
cigars. 
Participants 2,7,9, and 5 quit smoking, and smoking abstinence was 
maintained by Participants 2,7, and 5 from post-intervention up until the second 
monthly follow-up, while Participant 9 relapsed shortly after the post-intervention 
phase, they managed to reduce their cigarette intake down to two cigarettes per day. 
Although Participants 4, 6, 8, 9, and 10 did not quit smoking, they showed 
great reductions in their cigarette intake and were successful in maintaining these 
reductions in the follow-up phases. Participant 1 and 3 showed no changes 
whatsoever in their smoking intake. 
Figure 5 shows that each participants score achieved on the CDS 
decreased from baseline to post-intervention. Thus, overall cigarette dependence 
decreased. 
Figure 6 shows that there was a lot of variability in CQSS scores from 
baseline to post-intervention. For Participants 1, 6, 3, 4, and 5 commitment to quit 
53 
 
increased. Whereas, commitment to quit levels for Participants 2,7,8, 9, and 10 
decreased. 
Figure 7 shows that scores on the AAQ measure slightly increased from 
baseline to post-intervention for Participants 1, 2, and 9, and for Participant 5 the 
AAQ score increased from 9 to 30. For Participants 6, 7, 8, 3, 4, and 10 the AAQ 
scores decreased. Table 2 shows that there was no correlation between AAQ 
scores and a decrease in cigarette intake, and there was no correlation between 
AAQ scores and cravings to smoke cigarettes at the group level.  
Summary of Outcome Measures 
To summarise, cigarette intake and cigarette dependence levels 
significantly decreased but cravings to smoke did not decrease to a significant 
extent. Although most people were happy with the app, some suggestions for 
improvements were reported.  
Discussion 
My aim was to examine whether SmartQuit™ would be a successful 
treatment for smoking cessation with a New Zealand sample. Firstly, I 
hypothesised that SmartQuit™ would lead to a decrease in daily cigarette intake. 
Secondly, I hypothesised that those participants who obtained high scores on the 
Commitment to Quit Scale would have better chances for smoking noticeably less 
than what they did during the baseline phase. Thirdly, as SmartQuit™ is ACT 
based, and the goal of ACT is to increase acceptance and willingness of internal 
experiences, I expected acceptance levels (embracing internal experiences, e.g. 
thoughts, and feelings) to increase, and experiential avoidance (avoiding 
unwanted internal experiences) to decrease. Finally, I measured cravings to 
smoke, to see if they changed after the intervention.  
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Overall, the data suggest that SmartQuit™ is effective at reducing 
cigarette intake, decreasing experiential avoidance, increasing acceptance, and 
helping quit smoking. I will discuss these findings below.  
Daily Cigarette Consumption  
The effects of the acceptance-and-commitment-based smoking cessation 
intervention (SmartQuit™) were examined and noticeable reductions in cigarette 
intake and cravings to smoke were apparent. The average number of cigarettes 
smoked decreased from 16.6 to 5.74 per day, and the average number of cravings 
to smoke decreased from 14.8 to 9.19 per day. Eight of the ten participants had 
reduced their cigarette smoking levels at post-intervention. Three were no longer 
smoking during the post-intervention phase. At each of the two monthly follow-up 
phases, the three individuals who had quit had maintained abstinence. Thus, 
SmartQuit™ was effective overall in reducing the number of cigarettes smoked. 
As expected, the results indicated a significant reduction in cigarette intake 
at the group and at the individual level, as most individuals revealed a change, this 
finding was further supported by its large effect size.  
Consistent with my findings, Bricker and colleagues (2014) also reported 
reductions in cigarette intake and an increase in smoking abstinence for 
participants who used SmartQuit™, Bricker and colleagues included a 
comparison app (QuitGuide®), and individuals assigned to SmartQuit™ had 
higher quit rates than those who used QuitGuide®. Also consistent with my 
findings Brewer et al. (2011) found reductions in cigarette intake at post-
intervention, using Mindfulness Training, and these reductions were maintained 
during the follow-up phase. 
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Cravings to Smoke Cigarettes  
Previous research evaluating mindfulness practice has suggested that 
individuals learn to respond to cravings with awareness, and not automatically 
respond to cravings (Marcus & Zgierska, 2009). In striking contrast, Cognitive 
Behavioural Therapy focuses on attempting to reduce the number and intensity of 
cravings, through teaching clients to distract themselves from the cigarettes, and 
through cognitively restructuring thoughts associated with cravings to smoke 
(Forman, et al., 2007). Therefore, the focus of CBT-based approaches is to 
decrease and eliminate cravings, whereas, ACT-based approaches focus to help 
clients accept and not act on cravings, and under this approach cravings may or 
may not decrease. Given that the focus of ACT is not necessarily to decrease 
cravings, I examined the direction of the number of the cravings to smoke at post-
intervention. 
From baseline to follow-up, the number of cravings to smoke cigarettes 
reduced, although not significantly, and cravings ended completely for those 
individuals who had quit smoking. With that said, given the reduction in cigarette 
use, one may also expect that cravings would be higher at post-intervention. This 
was not the case in the current study, possibly because the mindfulness-based 
exercises provided in SmartQuit™ assisted participants to become more accepting 
of their cravings, and to let these cravings pass as opposed to giving in to them 
and smoking cigarettes.  
Cigarette Dependence  
I used the Cigarette Dependence Scale to assess the level of cigarette 
dependence. Scores achieved on the Cigarette Dependence Scale significantly 
decreased over the intervention. The decrease in cigarette dependence is evident at 
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both the group level, suggesting that after using the intervention, participants were 
less dependent on cigarettes.  To the best of my knowledge, the current study is 
the first to have used the Cigarette Dependence Scale as a tool to assess cigarette 
dependence at post-intervention, as previous studies have used the CDS to assess 
smoking outcomes at baseline only.  
I found no relation between cigarette dependence and a reduction in 
cigarette intake. Nor did the CDS predict smoking intake. 
Caponnetto and Polosa (2008) suggested that individuals who obtain 
scores of greater than seven on the FTND are less likely to succeed, due to being 
more likely to experience early relapse and intense withdrawal symptoms. Thus, 
excessive cigarette dependence levels can hinder success and make it harder to 
quit. High cigarette dependence levels may have hindered success in the current 
study, as only individuals with high cigarette dependence were recruited. 
 Girma, Assefa, and Deribew (2010) when assessing intention to quit, 
found that as the level of nicotine dependence increased, the likelihood for 
successful smoke-free outcomes decreased (Girma, Assefa, & Deribew, 2010; 
Lund, 2015). They also reported that individuals who had high levels of cigarette 
dependence had no intention to quit, thus cigarette dependence is not the only 
important factor, as the intention and commitment to quit also plays an important 
role. However, Borland and colleagues (2010) noted only moderate support for 
the possibility that higher levels of cigarette dependence predisposed individuals 
to relapse. Thus, it is possible that dependence levels were not the only factor that 
may have influenced treatment outcomes.  
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Commitment to Quit Scale 
I expected that participants with higher scores on the Commitment to Quit 
Scale during the baseline phase would have better smoking outcomes, however, 
this was not the case. Commitment to Quit scores did not predict smoking 
outcomes, and those individuals who did successfully quit smoking did not score 
higher on the Commitment to Quit Scale than other participants who did not quit.  
At the group level commitment levels decreased, however, this was not the 
case at the individual level, as scores for two of the three individuals who quit 
decreased, and two showed no change in smoking patterns, both receiving the 
lowest scores on this measure during the baseline phase. Thus, although higher 
scores did not predict successful outcomes, lower scores revealed an association 
with unsuccessful outcomes. These findings give rise to the idea that perhaps 
CQSS scores need to be above a certain level for someone to be successful in 
quitting. High levels of commitment to quit would make sense, given how hard it 
is to stop smoking. For one participant (Participant 3) the low CQSS score was 
related to the period of time they spent engaging with the app, which was 2 
weeks, and was one of the shortest periods. There was also an association with 
how often this participant engaged with the smartphone application, which was 
once per day. For Participant 1, I found no relationship between the low CQSS 
score and length of time spent engaging with the SmartQuit™ programme, or how 
frequently they opened the application. That being said Participant 1 had difficulty 
engaging with the app and did have periods where they stopped using the app as a 
result. The same was found for Participant 3 who also found the application 
difficult to navigate. Daily app use for Participant 1 was also relatively low as was 
the case for Participant 3, with daily app use at twice a day, whereas all other 
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participants used the app from 3-20 times a day. Also, these two individuals were 
the only two to disagree with the statement asking whether SmartQuit™ was 
appropriate for them. 
Psychological theories propose that motivation to quit predicts successful 
smoking cessation. Borland and colleagues (2010) examined whether motivation 
had a predictive relationship in quit attempts, and in abstinence. They concluded 
that although motivational factors played a role in encouraging individuals to 
initiate action to quit smoking, motivational factors did not serve as predicting 
variables for quitting smoking and abstinence (Borland, et al., 2010). Borland et 
al. also suggested that both quitting smoking and maintaining smoke-free 
outcomes is not a matter of commitment only, and also applies to volitional 
control. Thus, a number of other factors were also required. 
Kahler et al. (2007) reported a significant increase in commitment to quit 
smoking scores at quit date, and these higher levels of commitment were linked 
with greater smoking odds, at post-intervention, 16, and 26 weeks following 
participants’ quit dates. They also reported that the CQSS measure predicted 
smoking outcomes at post-intervention over and above cigarette dependence level, 
the importance of quitting, and self-efficacy for abstinence. 
Kale, Gilbert, and Sutton (2015) found that motivation may not 
successfully predict smoke-free outcomes, as those individuals who have high 
levels of motivation to quit smoking are usually those who are strongly addicted 
to nicotine, as, in spite of having a strong desire to quit smoking, they persist in 
smoking. It was then concluded that a high level of motivation to quit serves as a 
prompting factor to initiate quitting, rather than as a factor for maintaining 
abstinence, and they instead concluded that the level of cigarette dependence is 
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more important for smoking abstinence, particularly lower cigarette dependence 
levels. 
Acceptance 
Acceptance is a central component of ACT, with high levels of acceptance 
suggesting that individuals are no longer engaging in avoidant and control 
strategies in an attempt to reduce their internal experiences. I expected that 
acceptance levels from baseline to post-intervention would decrease. I measured 
this hypothesis with the AAQ. The intervention comparisons support the 
hypothesis, however, the decrease in AAQ scores was non-statistically significant. 
The effect size for this analysis (d = 0.07) was found to meet Cohen’s (1988) 
criteria for a small effect.  
Scores obtained on the AAQ measure were of importance in this study, as 
lower scores on this measure indicate high acceptance, and higher scores on this 
measure indicate high experiential avoidance. For the purposes of this study, 
higher acceptance relates to quitting success, as it means that participants were 
more accepting of internal experiences. In contrast, prior to the intervention 
participants obtained higher scores on the AAQ thus indicating that they were 
avoiding internal experiences. With the focus of both the framework of ACT, and 
the framework of the app being on increasing acceptance, and decreasing 
experiential avoidance, this finding was very important, in spite of the difference 
being non-significant. The reason for the reduction in acceptance levels not being 
significant could be attributed to the small sample, and the large variance in 
scores,  
At the individual level, those individuals who had obtained low scores on 
the AAQ measure during the baseline, scored high during the post-intervention, 
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and those individuals who obtained high scores during the baseline phase obtained 
low scores at post-intervention. This is an example of regression to the mean, 
whereby when measured again, extreme scores are closer to the mean (Bland & 
Altman, 1994). 
 Beharry (2008) in her study on the use of ACT to target public speaking 
reported that the mean AAQ scores had significantly decreased when the AAQ 
was administered last, following the intervention. Gifford et al. (2004) also found 
a decrease in experiential avoidance, and an increase in acceptance. Using 
SmartQuit™, Bricker et al. (2014) also reported that acceptance increased over 
the course of the intervention. They also found that participants who obtained low 
scores on the AAQ at baseline had better smoking outcomes (smoked less). 
However, the second finding was not found in the current study. Finally, Farriss, 
Zvolensky, DiBello, and Schmidt (2015) also reported higher acceptance levels. 
The findings of the current study were somewhat comparable with the findings 
from these studies, as these studies also noted an increase in acceptance and a 
decrease in experiential avoidance, however, these studies found a significant 
increase whereas I did not. Overall, I found an increasing trend in acceptance 
levels, and a majority of studies also favour this upward trend. Thus treatment 
outcomes for smoking cessation may be associated with ACT based change.  
Lacaille and colleagues (2014) in evaluating the effects of mindfulness 
skills on chocolate cravings mentioned that individual differences may influence 
individual abilities to learn the content offered by acceptance and commitment 
based therapies and that changes in acceptance cannot be attributed to the 
intervention. In respect to the current study, it could be that participants 
understood the intervention to different degrees.  
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The aim of ACT is not to eliminate or reduce the number of cravings to 
smoke cigarettes or relieve the distress produced by cravings. Rather the goal of 
acceptance-based strategies is to foster readiness to experience what cannot be 
controlled, while promoting behaviour that aligns with the desired goal. In 
respects to smoking cessation, the goal is not to change and avoid cravings but 
rather notice and accept cravings to smoke (Forman, et al., 2007). Therefore, the 
success of the SmartQuit™ program is not determined or dependent on whether 
cravings to smoke increase, decrease or remain constant.  
Engagement with SmartQuit™ 
When selecting a quit date at the beginning of the programme, a 7-14-day 
period was suggested. In the current study, all of the participants with the 
exception of one found this timeframe to be unrealistic, as each participant reset 
their quit date. 
The length of time spent engaging with the app, and the number of 
exercises completed on the application, were unrelated to whether someone was 
successful or not. 
Two participants who had not completed all of the exercises provided in 
SmartQuit™ gave up smoking and maintained abstinence. This suggests that not 
all of the activities are required and what is required is techniques and exercises 
that work with the user. However, a clinical trial revealed that those individuals, 
who completed all of the requirements of SmartQuit™, were 10 times more likely 
to quit smoking, compared to those individuals who did not complete all of the 
requirements (Bricker, et al., 2014). 
Also within the follow-up phase participants informed me of the exercises 
which were the most and least effective. The urge monster, the tug of war, and the 
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river exercises were reported as being the most useful. Instead of reporting which 
exercises were less useful, participants reported less useful aspects of the app 
instead. Therefore, there were no exercises that were thought as being less useful. 
The least preferred aspect of SmartQuit™ was that all eight of the exercises were 
readily available, in spite of the instructions suggesting that each exercise should 
be practiced two to three times before moving to the next exercise. Participants 
mentioned that for future users these exercises should be locked, and should be 
accessible on completing the previous exercise for the recommended two to three 
times.  Good aspects of the app were ownership of urges to smoke, and tips on 
how to deal with urges to smoke. Bad aspects of the application were time to 
navigate through the application and having no lock on exercises.  
Strengths 
There were several advantages of using a small-N, within-subject design. 
Firstly, there was no control condition, so all participants received the intervention 
and they each acted as their own control. Secondly, inter-subject variability was 
reduced. Thirdly, repeated measures allowed for stable assessments. Fourthly, 
individual characteristics could be used to determine the success of the 
intervention  (Butler, Sargisson, & Elliffe, 2011). Fifthly, a strength for using a 
single subject design is its ability to cater to individual needs, for instance, 
individuals could take as long as they needed to complete the intervention. 
Sixthly, it was easier to keep environmental variables constant both across 
participants, and conditions, and the effects of the intervention were observed 
relatively early. Finally, with individuals entering baseline and treatment 
conditions at varying stages, daily changes in behaviour could be observed first 
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hand, and if changes needed to be made, then there was time to make them early 
on in the study (Barker, Pistrang, & Elliot, 2002; Bryman, 2008). 
To measure daily smoking consumption, cravings to smoke, cigarette 
dependence, commitment levels, and acceptance and action levels, self-reported 
data were used. Self-reports help make phenomenological information available, 
which are otherwise unavailable, such examples include individual experiences 
and idiosyncratic states (Bryman, 2008).  
In the present study, I was present at the time at which the questionnaires 
were completed. Thus, I addressed any difficulties faced with answering the 
questions, I checked questionnaires after completion for missing data, and I was 
aware that the questionnaires were completed by the right person. 
A strength of delivering interventions through smartphones is the 
availability of the intervention for individuals. More so, the exercises provided in 
SmartQuit™ provided autonomy and freedom to participants, as the exercises 
were self-paced, and structured to meet the needs of each participant. 
Limitations  
Limitations of the current study must be acknowledged. Firstly, majority 
of the data were self-reported. Self-reported data can be problematic in that there 
is potential for integrity to be compromised because individuals may be lying or 
mistaken, lack the words required to express their responses, and their responses 
may be exaggerated (Barker, Pistrang, & Elliot, 2002). Some of these self-report 
data limitations were avoided, as I was present when participants completed the 
questionnaires, and this provided participants with the opportunity to ask any 
questions.  
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As outlined by Bryman (2008) there are several disadvantages for self-
completed questionnaires, for one, self-completed questionnaires prevent 
researchers from prompting, and probing for more information. Secondly, self-
completed questionnaires are not appropriate for all respondents. Thirdly, self-
completed surveys do not allow additional data to be collected. Fourthly, self-
completed surveys pose a risk for missing data, and difficult questions, and 
finally, there is no knowing who completed the questionnaires.  
Another issue could be that asking participants to record their intake and 
cravings to smoking may itself have lowered smoking and craving rates, as when 
we are asked to track our behaviour, we have a tendency to attempt to make the 
behaviour seem more socially acceptable as we are aware that someone will see it 
(Donaldson, & Grant-Vallone, 2002).  Future research could look into using 
objective measures of smoking in addition to self-report.  
Secondly, the sample size of 10 participants was relatively small, and 
having a small sample size means that the effects of the intervention may be hard 
to generalise. However, recruiting a large sample would have been difficult.  I 
note that while results failed to meet statistical significance, small-N designs are 
typically subject to graphical analysis. Freeman and Tyrer (2006) suggest that 
although the common approach for group studies is to use inferential statistics for 
analysing the effectiveness of treatment, visual inspection of graphs is enough, as 
each participant in a small-N design are assessed both frequently and intensively, 
so the effect is probably real, and thus there is no need for inferential statistics or 
significance. 
Thirdly, a lot of the discussion about the SmartQuit™ program took place 
after the questionnaires in the post-intervention phase was completed. This is 
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problematic because these discussions were not recorded, thus they could not be 
included in the results. However, these conversations did provide an insight into 
participant’s thoughts on the SmartQuit™ program. Future research could 
consider interviewing participants to capture this data. 
Finally, while a large number of participants initially expressed an interest 
to partake in the current study, only 10 completed the intervention, as the other 18 
either did not meet the criteria of the study, declined to take part in the study, or 
did not start the study. Factors that may have influenced dropout include 
commitment and motivation (Branstetter, Horn, & Zhang, 2009). Sidani (2014) 
stated a low readiness to quit, and schedule conflicts as factors for pre-inclusion 
attrition. Factors such as health, their appraisal of the treatment, and feeling they 
may not be meeting the study requirements were reported to influence post-
inclusion attrition. Curtin et al. (2000) noted that dropout rates were higher in pre-
inclusion at 30-50%, and for post-inclusion, the dropout rate was 10-50%. In my 
study, a higher attrition rate was observed at pre-inclusion as well. Future research 
could look into contacting the people who did not take part and ask them why. 
Research on smoking cessation using an ACT framework and smartphones 
could be extended by including smokers with low cigarette dependence and low 
commitment to quit, as literature suggests that individuals who score higher on 
these two measures face better smoking outcomes (Rohsenow, Martin, Tidey, 
Monti, & Colby, 2013). I excluded individuals with low scores from the current 
study, thus no comparison could be made with individuals who have high scores 
on these measures. Future research could also compare SmartQuit™ to another 
smoking cessation method, measure cravings for a longer period to assess whether 
smoking abstinence reveals a decrease in cravings over time. 
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Conclusions 
Using a single subject A-B-A-C design I explored whether SmartQuit™ would be 
a useful treatment for smoking cessation for a New Zealand population. Following 
the SmartQuit™ programme, participants smoked fewer cigarettes, reported fewer 
cravings to smoke, and had lower scores on the Cigarette Dependence Scale 
(lower cigarette dependence). However, the Commitment to Quit Scale did not 
predict smoking outcomes. Overall, the findings of the present study support 
SmartQuit™ as a good option for smoking cessation. 
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Appendix B 
University of Waikato 
School of Psychology 
INFORMATION SHEET- STOPPING SMOKING USING SMARTQUIT™ 
FOR HEALTH PRACTITIONERS 
  
 
My name is Satvir Singh, and I am a Master’s student at the University of 
Waikato. I would like talk to you about my research study. I require your help 
with discussing and actively promoting my research study with clients at your 
health care centre. 
About this study 
I seek to not only recruit participants from the general public but also to undertake 
socially just research, by ensuring that Māori individuals and Māori perspectives 
are included in each phase of this programme. Research shows that Māori are 
highly represented in smoking statistics (Glover, Fraser, & Nosa, 2012). 
Therefore, as a group, Māori may benefit from smoking cessation interventions. 
Within this study I will test the effectiveness of a smoking cessation smartphone 
application (SmartQuit™), which is based on acceptance and commitment therapy 
principles, at reducing smoking craving and cigarette consumption. This will be 
achieved through five phases.  I expect that the results will be consistent with 
those of Bricker and colleagues (2014) who found this smartphone app to be 
highly effective in reducing cravings, urges and the number of cigarettes smoked.  
Information about the smartphone app (SmartQuit™) 
SmartQuit™ was developed by Johnathon Bricker in 2014. Which is an evidence-
based smartphone application that uses acceptance commitment therapy 
techniques as a means of delivering smoking cessation. The underlying goal of 
SmartQuit™ is to teach individuals techniques to deal with and accept their 
cravings and urges to smoke. This app differs from other smoking cessation apps 
in that it goes beyond tracking how many cigarettes have been smoked and 
instead tracks urges to smoke cigarettes. 
SmartQuit™ will be offered free of charge within this study for six months for 
each participant and can be used at the person's own pace.  The programme begins 
with an introduction and access to a personalised quit plan, which can be updated 
at any time of the programme.  Following the quit plan, the user tracks their urges 
to smoke on a daily basis. The user is also expected to complete daily exercises. 
There is a total of eight exercises to complete and each time one activity is 
completed, another is unlocked.  Additionally, for every 10 urges recorded and for 
every activity completed, a badge is received.   The app also includes a section for 
anytime coaching which includes; stories of others, tips to manage urges and ask a 
coach section. 
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Do you know of any clients that meet these criteria? 
The requirements to partake in the study will be as follows; 1) 18 years of age or 
older, 2) must smoke more than 10 cigarettes per day in the past 12 months, 3) 
they must want to quit smoking in the near future, 4) they must have access to a 
smartphone, that is compatible with the smartphone app (Smart Quit), 5) they 
must consent to not use any other interventions or medication throughout the 
experimental phase, and 6) they must agree to partake in the follow-up phase and 
complete the follow-up surveys.  
 
If you know of clients that meet the criteria mentioned here and have expressed an 
interest to quit smoking, then could you please mention my study to them, and if it 
sounds interesting to them then have them contact me on the details mentioned 
below. 
 
Kind regards, 
Researcher: Satvir Singh 
Department of Psychology 
University of Waikato 
sks42@students.waikato.ac.nz 
Here are details for both of my supervisors as well as the convenor of the ethics 
committee. Feel free to contact myself or my supervisors if you have any 
further questions regarding the nature of the research. Also, should you 
have any concerns about the ethical conduct of the researcher then please 
feel free to contact James Mc Ewan. 
 
Supervisor: Doctor Rebecca Sargission 
School of Psychology  
University of Waikato 
Email: rebeccas@waikato.ac.nz 
 
Supervisor:  Doctor Nicola Starkey  
School of Psychology  
University of Waikato 
Email: nstarkey@waikato.ac.nz 
 
This research project has been approved by the School of Psychology Research 
and Ethics Committee of the Faculty of Arts and Social Sciences, 
University of Waikato. Any questions about the ethical conduct of this 
research may be sent to the convenor of the Research and Ethics 
Committee (currently Dr James McEwan, phone 07 838 4466 ext. 8295, 
email: jmcewan@waikato.ac.nz) 
 
Support of this study 
This research study will be supported by 2Morrow, Inc.  
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Appendix C 
The Heaviness of Smoking (HSI) 
The heaviness of smoking index consists of FTND item 1 and item 4, using the 
same response scales and calculating the total score using the sum on those two 
items. 
1) How soon after you wake up do you smoke your first cigarette? 
a) Within 5 minutes 
b) 5-30 minutes 
c) 31-60 minutes 
d) 60+ minutes 
 
2) How many cigarettes do you smoke? 
a) 10 or less 
b) 11-20 
c) 21-30 
d) 31 or more 
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Appendix D 
Eligibility Survey 
Please circle the response that best applies to you. 
1. How old are you 
15-24   25-34 
35-44   45-54 
55-64   65+ 
 
2. Indicate the number of cigarettes you smoke per day in the past 12 
months; 
0-10   11-20  21-30  31 or more 
 
3. How soon after waking up do you smoke your first cigarette? 
Within five minutes 6-30 minutes  31-60 minutes  After 
60 minutes 
 
4. Do you want to quit smoking in the near future? 
Yes         
No 
 
5. Do you have access to a smartphone? 
Yes 
No 
 
6. Are you currently using medication or an intervention (e.g nicotine 
replacement products) in an attempt to quit smoking? 
Yes 
No 
 
7. Can you speak and understand English? 
Yes 
No 
 
8. Are you currently seeking or undergoing psychological treatment? 
Yes  
No 
 
9. Have you been diagnosed with a psychotic or affective disorder? 
Yes  
No 
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Appendix E 
The Cigarette Dependence Scale 
Below you will find a list of statements. Please circle the response that applies to 
you. 
1) Please rate your addiction on a scale of 0-100 
I am NOT addicted at all=0 
I am extremely addicted to cigarettes=100 
 
a) 0-20    
b)  21-40  
c) 41-60    
d) 61-80 
e) 81-100 
 
2) On average, how many cigarettes do you smoke per day, based on the last 
12 months? 
0-5   6-10 
11-20   21-29 
30+ 
 
3) Usually, how soon after waking up do you smoke your first cigarette, 
based on the last 12 months? 
0-5    6-15 
16-30   31-60 
61+ 
 
4) For you, quitting smoking would be 
Impossible   Very difficult       
Fairly difficult   Fairly easy       
Very easy 
 
Please indicate whether you agree with each of the following statements: 
 
5) After a few hours without smoking, I feel an irresistible urge to smoke 
Totally disagree   Somewhat disagree 
Neither agree or disagree   Somewhat agree 
Fully agree 
 
6) The idea of not having any cigarettes causes me stress 
Totally disagree   Somewhat disagree 
89 
 
Neither agree or disagree   Somewhat agree 
Fully agree 
 
7) Before going out, I always make sure that I have cigarettes with me 
Totally disagree   Somewhat disagree 
Neither agree or disagree   Somewhat agree 
Fully agree 
 
8) I am a prisoner of cigarettes 
Totally disagree   Somewhat disagree 
Neither agree or disagree   Somewhat agree 
Fully agree 
 
9) I smoke too much 
Totally disagree   Somewhat disagree 
Neither agree or disagree   Somewhat agree 
Fully agree 
 
10) Sometimes I drop everything to go buy cigarettes 
Totally disagree   Somewhat disagree 
Neither agree or disagree   Somewhat agree 
Fully agree 
 
11) I smoke all the time 
Totally disagree   Somewhat disagree 
Neither agree or disagree   Somewhat agree 
Fully agree 
 
12) I smoke despite the risks to my health 
Totally disagree   Somewhat disagree 
Neither agree or disagree   Somewhat agree 
Fully agree 
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Appendix F 
Commitment to Quitting Smoking Scale 
Below you will find a list of statements. Please rate how true each statement is for 
you by circling a number next to it. Use the scale below to make your choice.  
1 – Strongly disagree,    2 – Disagree,   
3 – Neither disagree nor agree, 4 – Agree,     
5 – Strongly agree  
1) I am willing to put up with whatever discomfort I have to in order to quit 
smoking. 
1  2   3   4   5 
2) No matter how difficult it may be. I won’t let myself smoke once I quit. 
1  2   3   4   5 
3) Feeling very anxious or restless won’t prevent me from quitting smoking. 
1  2   3   4   5 
4) Even if I really want one. I won’t let myself pick up a cigarette once I quit. 
1  2   3   4   5 
5) No matter how much I crave a cigarette when I quit. I’m going to resist the 
urge to smoke. 
1  2   3   4   5 
6) Feeling very depressed or sad won’t prevent me from quitting smoking. 
1  2   3   4   5 
7) I’m not going to let anything get in the way of my quitting smoking. 
1  2   3   4   5 
8) Feeling very angry and irritable won’t prevent me from quitting smoking. 
1  2   3   4   5 
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Appendix G 
Acceptance and Action Questionnaire 
Below you will find a list of statements. Please rate how true each statement is for 
you by circling a number next to it. Use the scale below to make your choice.  
1 – Never true ,  2 – very seldom true ,   3 – Seldom true ,                       
4 – Sometimes true ,    5 – Frequently true ,             6 – Almost always true ,  
7 – Always true  
 
1) My painful experiences and memories make it difficult for me to live a life 
that I would value. 
1    2     3     4     5    6    7 
2) I'm afraid of my feelings. 
1    2     3     4     5    6    7 
3) I worry about not being able to control my worries and feelings. 
1    2     3     4     5    6    7 
4) My painful memories prevent me from having a fulfilling life. 
1    2     3     4     5    6    7 
5) Emotions cause problems in my life. 
1    2     3     4     5    6    7 
6) It seems like most people are handling their lives better than I am. 
1    2     3     4     5    6    7 
7) Worries get in the way of my success. 
1    2     3     4     5    6    7 
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Appendix H 
University of Waikato 
School of Psychology 
Information Sheet - Stopping smoking using SmartQuit™ 
  
 
My name is Satvir Singh, and I am a Master’s student at the University of 
Waikato. I would like to invite you to participate in my study, which will be using 
a smart phone app (SmartQuit™) to help reduce and stop smoking. SmartQuit™ 
is based on principles called acceptance and commitment therapy (ACT) which 
has been shown to help reduce cigarette cravings, urges and intake.  Previous 
research has found that people do not want to smoke as much after using 
SmartQuit™. 
What will be required of you: 
This study will consist five parts: 
 
1. You and I will meet to complete questionnaires that will collect 
information, such as your age, gender, ethnicity, nicotine dependence, 
smoking behaviours and your commitment to quit smoking.  
During this meeting, you will also be given a wallet sized notebook in 
which you will be asked to collect information on your smoking amount, 
cravings and urges for a period of 3-21 days. 
2. During this time, I will contact you daily via text message to ask you for 
your counts for the day. 
3. After you have completed your notebook I will contact you again and give 
instructions to download SmartQuit™ free of charge. This programme will 
prompt you to complete a quit plan, complete daily exercises and choose a 
quit date. 
4. When you have reached your quit date, you will again be asked to record 
your smoking, cravings and urges for another period of 3-21 days, and to 
send these to me via text message.   
5. A month after this, you will be asked to complete a follow-up survey, 
which will assess your satisfaction with SmartQuit™ and your smoking 
outcomes. This survey will be repeated again a month later. 
 
What will be done with your information:  
Your name will be coded and will not be attached or linked to any of your 
collected data. This is to ensure that in no way data will be traceable to you. All 
information provided by you will be stored securely at the School of Psychology 
at the University of Waikato, for a period of 5 years. The findings from this study 
will be published as a written report as requirements for my Master’s thesis, these 
findings will be made available at the School of Psychology office. A summary of 
the findings will also be sent to you should you request it, on the consent form. 
Can I withdraw 
Participation in this study is entirely voluntary (your choice) and should you 
change your mind, then you may withdraw without any penalty.  
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If I am not happy with my outcomes, can I try again? 
You will have free access to the smart phone app for 6 months and, after reaching 
your quit date, you will receive a notification asking how your quit went and 
whether you were successful or not. If you were not successful then the app will 
allow you to reset your quit date and start again, you may do this as many times as 
you like, provided it is within the 6-month time frame. 
What’s next 
If this sounds interesting to you and you would like further information or you 
would like to take part in this study, then please contact me via email and we can 
negotiate a time to meet. 
Kind regards, 
Researcher: Satvir Singh 
Department of Psychology 
University of Waikato 
sks42@students.waikato.ac.nz 
Here are details for both of my supervisors as well as the convenor of the ethics 
committee. Feel free to contact myself or my supervisors if you have any 
further questions regarding the nature of the research. Also should you 
have any concerns about the ethical conduct of the researcher then please 
contact James Mc Ewan. 
 
Supervisor: Doctor Rebecca Sargission 
School of Psychology  
University of Waikato 
Email: rebeccas@waikato.ac.nz 
 
Supervisor:  Doctor Nicola Starkey  
School of Psychology  
University of Waikato 
Email: nstarkey@waikato.ac.nz 
 
This research project has been approved by the School of Psychology Research 
and Ethics Committee of the Faculty of Arts and Social Sciences, 
University of Waikato. Any questions about the ethical conduct of this 
research may be sent to the convenor of the Research and Ethics 
Committee (currently Dr James McEwan, phone 07 838 4466 ext. 8295, 
email: jmcewan@waikato.ac.nz) 
 
Support of this study 
This research study will be supported by 2morrow, Inc.  
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Appendix I 
Consent Form 
Participant Copy 
Research Project:  Stopping smoking using SmartQuit™  
 
Declaration by participant: 
Please complete the following checklist.  Tick () the appropriate 
box for each point.  
YES NO 
1. I have read the Participant Information Sheet (or it has been read to 
me) and I understand it.   
  
2. I have been given sufficient time to consider whether or not to 
participate in this study 
  
3. I am satisfied with the answers I have been given regarding the study 
and I have a copy of this consent form and information sheet 
  
4. I understand that taking part in this study is voluntary (my choice) 
and that I may withdraw from the study at any time without penalty 
  
5. I have the right to decline to participate in any part of the research 
activity 
  
6. I know who to contact if I have any questions about the study in 
general. 
  
7. I Understand that my participation in this study is confidential and 
that no material, which could identify me personally, will be used in 
any reports on this study. 
  
8. I know not to use any other interventions or medications such as 
nicotine replacement products, during all phases of the study. 
  
9. I agree to being approached to complete two short follow-up surveys. 
The first follow-up will be completed one month after the completion 
of the app, and the second will be completed a month after the first 
follow-up. 
  
10. I wish to receive a copy of the findings   
Email address:   
Or postal address if you want to receive a hard copy: 
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I agree to participate in this research project and I understand that I may withdraw 
at any time. If I have any concerns about this project, I may contact the convenor 
of the Psychology Research and Ethics Committee (Dr James McEwan, Tel: 07 838 
4466 ext. 8295, email: jmcewan@waikato.ac.nz)  
Participant’s name (Please print): 
Signature: Date: 
 
Declaration by member of research team: 
I have given a verbal explanation of the research project to the participant, and 
have answered the participant’s questions about it. I believe that the participant 
understands the study and has given informed consent to participate. 
Researcher’s name (Please print): 
Signature: Date: 
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Appendix J 
Demographic Questionnaire 
1) Gender:    Female   Male   Transgender 
2) What is your age:   18-24,  25-33,   33-44, 45-54,  54-65, 66 and older 
3) How would you describe your ethnicity 
European/ Pakeha   Pacific Island 
Māori    Asian  
Indian  
Other_____________________________________     
4) Does anyone else in your household smoke    yes     no 
5) Do you have close friends that smoke      yes    no 
6) If married or in a long term relationship, does your partner also smoke  
yes            no 
7) How many cigarette smokes do you have per day 
8) Number of years you have been a regular cigarette smokers____________ 
9) How much social support do you have to quit smoking 
A lot  Somewhat  Very little Not at all 
10) Have you tried quitting before yes  no 
11)  If yes how many times have you attempted to quit__________________  
12) If answered yes to question 10, were you successful  
Yes   No  For a while     
13) If you answered yes to question 10, then which methods did you use ;  
Cold turkey  Nicotine replacement   Quitline  
E-cigarette  Hypnosis    Acupuncture  
Herbs/Supplements Laser therapy    Medication 
Other_______________________________________________________ 
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 Appendix K  
Introduction to the SmartQuit™ Programme 
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Appendix L 
Personalised Quit Plan (completed example) 
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Appendix M 
 
Urge Tracker 
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Appendix N 
 
Tracking Urges that have passed 
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Appendix O 
Notification to Reset Quit Date 
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Appendix P 
Administrator’s Page 
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Appendix Q 
Follow-up Survey 
Please circle the response that is the best fit for you. Circle only one response for 
each statement. 
1. How many cigarettes do you have per day;   
0   5+  10+   20+     
other________________ 
 
2. Smoking status;  
I quit   I did not quit   
   
3.  I reset my quit date? 
Yes   No 
 
4. I relapsed while using Smart Quit: 
 Yes   No 
 
5. If answered yes to the question above, how many times did you reset your 
date 
 0-2   2-4   4-6  6-8   8-10 
 
6. I am happy with my progress   
strongly agree  agree    
undecided  disagree      
strongly disagree 
 
7. My thoughts on smoking have changed;    
strongly agree  agree    
undecided   disagree   
strongly disagree 
 
8. My family and friends noticed a difference in my smoking behaviours;  
yes   no   maybe 
 
9. I still experience cravings and urges to smoke;  
strongly agree  agree    
undecided            disagree  
strongly disagree  
 
10.  If agreed with the statement above, then how strong are these cravings 
and urges to smoke; 
1  2 3 4 5 6 7 8 9 10 
 
106 
 
11. How do you cope with these cravings and urges on a scale of 1-10: 
1  2 3 4 5 6 7 8 9 10 
 
12. Are there particular situations that trigger urges and cravings  
strongly agree  agree    
undecided   disagree   
strongly disagree 
 
13. If answered yes, then please describe 
it/them_____________________________________________________ 
 
14. Is there a particular time when your cravings and urges are high    
yes   no   maybe 
 
15. My urges to smoke have;    
reduced     increased     ended completely 
 
16. SmartQuit was appropriate for me;    
strongly agree  agree       
undecided  disagree     
strongly disagree  
 
17. How many times on average did you open the app each 
day________________________________________________________ 
 
18. How many times on average did you open the app each 
week_______________________________________________________ 
 
19. What aspect of the app did you like the 
most_______________________________________________________ 
 
20. What aspect of the app did you dislike the 
most_______________________________________________________
___________________________________________________________ 
 
21. Name two strategies that you learnt within this programme that you 
thought were the most 
effective____________________________________________________
___________________________________________________________ 
 
22.  Would you recommend this programme to anyone in the future;  yes    no    
 
23.  I completed each activity; once, twice, three times, and +four before 
beginning the next activity. 
 
24. What type of person would you recommend this programme to; light 
smoker, medium smoker or a heavy smoker. 
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25.  I used the programme; on a regular basis, only when I needed to record 
urges when I received notifications only  
 
26. What factors made you use the app 
more_______________________________________________________
___________________________________________________________ 
 
27. What factors made you use the app 
less________________________________________________________
___________________________________________________________ 
 
28.  Do you think that there is room for improvement in the app; 
strongly agree  agree    
undecided    disagree   
strongly disagree 
 
29. If you agreed to the statement above, then please describe 
where______________________________________________________
___________________________________________________________ 
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Appendix R 
Summary of SmartQuit™ Exercises 
 
Exercise name    Exercise description 
Awareness When preparing to quit smoking, one 
must become aware of their normal 
smoking patterns, e.g cravings, and what 
their usual approach to dealing with 
urges is. In this exercise, users are asked 
to pay attention to each urge they have 
to smoke, and record this urge on the 
urge tracker provided in the app. 
Learning to become aware of cravings to 
smoke, is a useful technique later on the 
app, as the SmartQuit™ program 
teaches new strategies to deal with 
cravings later on. 
Don’t think The aim of this exercise is to not think. 
As attempting to stop thinking about 
smoking, increases smoking related 
thoughts, and persistence to smoke 
cigarettes. An increased awareness will 
increase chances for success in the 
SmartQuit™ programme. In this 
exercise asks users to notice what 
happens when they try not to think about 
smoking, and whether this increases 
cigarette intake, and urges to smoke.  
Urge Monster- Drop the Rope Users are first asked to visualise that 
their urges to smoke are similar to a 
monster, an urge monster. Next users are 
to visualise that they are having a tug  
match with the urge monster, and in-
between the monster and the user is a 
bottom less pit, and should the user fail 
or lose then they will fall into the pit. 
The goal of this exercise is to learn to 
stop pulling the rope and drop the rope. 
Are you willing Users are taught that the battle with the 
urge monster may be won in the short 
run, but this win is not long lasting, as 
the monster will come back.  
5 Senses The user is asked to see their smoking 
urges in relation to their five senses. 
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Leaves on a Stream The idea of this activity is to consider 
thoughts related to smoking as leaves, 
and to let them float down a stream. 
Practicing this exercise leads to a seven 
times higher chance of quitting. 
Finger trap The user is asked to imagine that life is 
like a finger trap, and the more the user 
pulls on the trap the more restricted they 
will be. 
Having the Thought Labelling urges as urges and thoughts as 
thoughts can provide the user with a 
sense of control. 
  
 
